Subcutaneous Biologics Market

Chapter Outlines

Chapter 2 is an executive summary of key insights captured during our research. It offers a high-level view on the likely evolution of subcutaneous biologics, formulation technologies and drug delivery systems market, in the short to mid and long term.

Chapter 3 provides a general introduction on different types of therapeutic molecules (biologics and small molecules) comparing their characteristics, such as molecular size, molecular weight, molecular structure, immunogenicity, stability and manufacturing. The chapter also highlights different types of biologically derived products that are currently being developed by several players in the industry. Additionally, it includes information on the various challenges associated with the parenteral route of drug delivery, specifically those related to the traditional intravenous (infusion) route. Further, this chapter discusses about subcutaneous formulations, which includes different approaches of delivery of such biologics, method of administration, advantages and limitations associated with this route, along with the relevant regulatory guidelines.

Chapter 4 includes information on around 120 subcutaneous biologic drug candidates that are currently approved. The chapter features an elaborate analysis of marketed biologics based on several relevant parameters, such as approval year, type of molecule (antibody, nucleotide, protein, vaccine and others), type of therapy (monotherapy and combination therapy), route of administration (subcutaneous, intravenous and intramuscular), method of administration (infusion and injection), dosing frequency, dose concentration (in mg/ml), target disease indication(s) (anemia, arthritis, asthma, diabetes, growth failure, growth hormone deficiency, idiopathic short stature, immunodeficiency, infertility, multiple sclerosis, neutropenia, osteoporosis, psoriasis, rheumatoid arthritis and turner syndrome), therapeutic area (autoimmune disorders, blood disorders, bone disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders) and type of drug delivery device (vial, cartridge, prefilled syringe, pen-injector, auto-injector and other devices). In addition, it provides details on the companies offering these approved subcutaneous biologics, along with information on their year of establishment, company size, geographical location and leading developers (in terms of number of approved subcutaneous biologics). 

Chapter 5 includes information of over 340 subcutaneous biologics that are currently in clinical stage of development. The chapter features an elaborate analysis of clinical-stage biologics based on several relevant parameters, such as phase of development (phase I, phase II, Phase III, and FDA registration), mechanism of action (inhibition, modulation, stimulation and others), type of molecule (antibody, antisense oligonucleotides, protein, small interfering RNA, vaccine and others), type of therapy (monotherapy and combination therapy), dosing frequency, target disease indication(s) (asthma, atopic dermatitis, breast cancer, Crohn’s disease, lung cancer, myasthenia gravis, non-alcoholic steatohepatitis, prostate cancer, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, type I diabetes, type II diabetes and ulcerative colitis ), therapeutic area (autoimmune disorders, bone disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, hormonal disorders, infectious disorders, inflammatory disorders, kidney disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders and other disorders)and special designation(s) awarded (if any). In addition, it provides details on the several companies engaged in the development of clinical-stage subcutaneous biologics, based on the year of establishment, company size, location of headquarters and leading players (in terms of number of clinical-stage drugs).

Chapter 6 is an insightful success protocol analysis of the leading subcutaneous biologics, biologics (in terms of value creation), taking into consideration several relevant parameters, such as drug efficacy / success rate, target disease indication burden, global competition (with respect to industry players), therapy price, geographical reach and disease prevalence.

Chapter 7 includes information on over 30 subcutaneous formulation technologies. It features an elaborate analysis of clinical-stage biologics based on several relevant parameters, such as fundamental principle of technology (amino acid interaction, complex formation, encapsulation and others), type of molecule (biologics and small molecule), route of administration (intramuscular, intraocular, intravenous, local (unspecified), oral, pulmonary, subcutaneous and others), therapeutic area (autoimmune disorders, genetic disorders,  isank-deficiency disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, other disorders) and primary advantage(s) offered. In addition, it provides details on the subcutaneous formulation technologies providers along with information on their year of establishment, company size and location of headquarters. 

Chapter 8 features an insightful company competitiveness analysis of the subcutaneous formulation technology developers, based on several relevant parameters, such as the company’s technology strength (taking into consideration years of experience, type of molecule, route of administration, therapeutic area and advantage(s) offered), and partnership strength (in terms of the number of partnerships inked and type of agreement).

Chapter 9 provides detailed profiles of key subcutaneous formulation technology providers engaged in this domain. Each profile features a brief overview of the company (including information on the year of establishment, number of employees, location of headquarters and key executives), details related to its financial information (if available), list of drug candidates developed using the formulation technology, details related to its recent developments, and an informed future outlook.

Chapter 10 features an analysis of recent partnerships and collaborations that have been inked by several stakeholders engaged in this domain, pre-2016-2021. The chapter includes a brief description of the partnership models (including licensing agreement, formulation development agreement, product development agreement, R&D agreement, manufacturing and supply agreement, product development and commercialization agreement, joint venture and other related agreements). Additionally, it comprises of analysis based on the year of partnership, type of partnership, type of partner, therapeutics area and focus area. Further, it consists of a schematic representation showcasing the players that have forged the maximum number of alliances. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 11 features an elaborate discussion on subcutaneous delivery systems with special focus on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, novel drug reconstitution systems, prefilled syringes and implants. The chapter includes a detailed analysis based on specific parameters for each device category, namely [A] large volume wearable non-insulin biologics injectors based on their phase of development, type of device, actuation mechanism, technology used, route of administration, method of administration, therapeutic area, type of dose, storage volume / capacity, usability, availability of prefilled drug reservoir, availability of connectivity, drug compatibility, availability of drug containers and key players, [B] large volume wearable insulin biologics injectors based on their phase of development, type of device, type of dose, storage volume / capacity, usability, combination insulin, non-interoperable devices, availability of prefilled drug reservoir, availability of continuous glucose monitoring (CGM) / blood glucose meters (BGM) system, availability of automated insulin delivery (AID) feature, automatic insulin delivery (AID) / artificial pancreas, availability of connectivity, availability of device control features and key players, [C] drug device combination products based on their phase of development, type device, mechanisms of action, technology used, route of administration, method of administration, therapeutics area, type of dose, storage volume/ capacity, usability, drug compatibility, drug container and key players, [D] autoinjector, by actuation mechanism, route of administration, type of dose, storage volume / capacity, usability, type of primary container, type of feedback mechanisms, and key players [E] pen-injectors based on their type of dose, storage volume / capacity, usability, and key player, [F] needle-free injection systems based on their phase of development, actuation mechanisms, therapeutic area, usability and key players  [G] novel drug reconstitution systems based on their volume of container, usability, type of device, type of chambers, physical state of drugs, container fabrication material and key player, [I] prefilled syringes based on their storage volume / capacity, barrel fabrication material, number of barrel chamber, type of needle system and key players and [J] implants based on their phase of development, therapeutic area, implant material, treatment duration, type of delivery system and key players.

Chapter 12 features an insightful product competitiveness analysis of the subcutaneous delivery system, such as large volume wearable injectors, autoinjectors, needle-free injectors and pre-filled syringes, taking into consideration the supplier power and product specific information.

Chapter 13 presents an elaborate market forecast analysis, highlighting the future potential of the approved subcutaneous biologics market till 2035. Additionally, the chapter includes future sales projections of various approved subcutaneous biologic drug candidates. The chapter presents a detailed market segmentation on the basis of type of biologic (antibodies, nucleotides, proteins, vaccines and other biologics), [B] type of therapy (monotherapy, combination therapy, and both (monotherapies and combination therapies)), [C] therapeutic area (autoimmune disorders, blood disorders, bone disorders, cardiovascular disorders, genetic disorders, hormonal disorders, infectious disorders, inflammatory disorders, metabolic disorders, neurological disorders, oncological disorders, respiratory disorders, women’s health  disorders, and other disorders) and  [D] geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World).

Chapter 14 presents an elaborate market forecast analysis, highlighting the future potential of the subcutaneous formulation technology market till the year 2035. The chapter presents a detailed market segmentation on the basis of [A] type of payment (milestone payments and upfront payments),  [B] fundamental principle (amino acid interaction, complex formation, encapsulation and other fundamental principles), [C] end user (biopharmaceutical companies, biotechnology companies, contract development and manufacturing organizations, educational institutes, investors and other end users), [D] therapeutic area (autoimmune disorders, genetic disorders, infectious disorders, metabolic disorders, oncological disorders, ophthalmic disorders and other disorders) and [E] geographical regions (North America, Europe and Asia).

Chapter 15 presents an elaborate market forecast analysis, highlighting the future potential of the approved subcutaneous biologics market till the year 2035. In addition, it provides a 14-year forecast of subcutaneous delivery systems, including large volume wearable injectors, autoinjectors, prefilled syringes, needle-free injection systems and novel drug reconstitution systems.

Chapter 16 provides a detailed analysis capturing the key parameters and trends that are likely to impact the industry’s evolution, under an elaborate SWOT framework; it also includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall subcutaneous biologics market. 

Chapter 17 is a summary of the overall report. In this chapter, we have provided a list of the key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 18 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Deborah Bitterfield (Chief Executive Officer and Founder, Lindy Biosciences), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), Steve Prestrelski (Chief Scientific Officer and Founder, Xeris Pharmaceuticals), Hong Qi (Vice President, Product Development, Xeris Pharmaceuticals), Scott Coleman (Former Sr. Scientist Formulation, Xeris Pharmaceuticals), David Daily (Chief Executive Officer and Co-Founder, DALI Medical Devices), Michael Reilly (Chief Executive Officer and Co-Founder, Excelse Bio), Poonam R Velagaleti (Co-Founder, i-novion), Michael Hooven (Chief Executive Officer, Enable Injections), Frederic Ors (Former Chief Executive Officer, Immunovaccine Technologies), Patrick Anquetil (Chief Executive Officer, Portal Instruments), Menachem Zucker (Vice President and Chief Scientist, Elcam Medical), Tiffany H Burke (Director, Global Communications, West Pharmaceutical Services), Graham Reynolds (Vice President and General Manager, Global Biologics, West Pharmaceutical Services) and David Heuzé (Communication Leader, MedinCell).

Chapter 19 is an appendix, which provides tabulated data and numbers for all the figures provided in the report. 

Chapter 20 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Different Types of Therapeutics Molecules
3.3. Biologically Derived Therapeutics
3.3.1. Types of Products
3.3.2. Routes of Administration and Formulations

3.3.3. Subcutaneous Administration
3.3.3.1. Approaches in Subcutaneous Delivery of Biologics
3.3.3.1.1. Reformulation
3.3.3.1.2. Differing Potencies
3.3.3.1.3. Novel Technologies

3.3.3.2. Methods of Subcutaneous Administration
3.3.3.3. Advantages of Subcutaneous Administration
3.3.3.4. Limitations of Subcutaneous Administration

3.4. Regulatory Considerations
3.4.1. Guidelines for Medical Devices
3.4.2. Guidelines for Drug Device Combination Products

3.5. Future Perspectives

4. APPROVED SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Approved Subcutaneous Biologics: List of Drugs
4.2.1. Analysis by Approval Year
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Method of Administration
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Dose Concentration
4.2.8. Analysis by Target Disease Indication(s)
4.2.9. Analysis by Therapeutic Area
4.2.10. Analysis by Type of Available Formulation

4.3. Approved Subcutaneous Biologics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Approved Subcutaneous Biologics

5. CLINICAL SUBCUTANEOUS BIOLOGICS: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Clinical-Stage Subcutaneous Biologics: List of Drugs
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Mechanism of Action
5.2.3. Analysis by Type of Molecule
5.2.4. Analysis by Type of Therapy
5.2.5. Analysis by Dosing Frequency
5.2.6. Analysis by Target Disease Indication(s)
5.2.7. Analysis by Therapeutic Area
5.2.8. Analysis by Special Drug Designation(s) Awarded

5.3. Clinical-Stage Subcutaneous Biologics: List of Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Geographical Location
5.3.4. Leading Developers: Analysis by Number of Clinical-Stage Subcutaneous Biologics

6. APPROVED SUBCUTANEOUS BIOLOGICS: SUCCESS PROTOCOL ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Success Protocol Analysis of Top Ten Approved Subcutaneous Biologics
6.3.1. BENLYSTA (Human Genome Sciences)
6.3.1.1. Overview
6.3.1.2. Development History
6.3.1.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.1.4. Success Protocol Analysis

6.3.2. BESREMi (PharmaEssentia)
6.3.2.1. Overview
6.3.2.2. Development History
6.3.2.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.2.4. Success Protocol Analysis

6.3.3. COSENTYX (Novartis)
6.3.3.1. Overview
6.3.3.2. Development History
6.3.3.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.3.4. Success Protocol Analysis

6.3.4. DARZALEX FASPRO (Halozyme)
6.3.4.1. Overview
6.3.4.2. Development History
6.3.4.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.4.4. Success Protocol Analysis

6.3.5. DUPIXENT (Regeneron Pharmaceuticals)
6.3.5.1. Overview
6.3.5.2. Development History
6.3.5.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.5.4. Success Protocol Analysis

6.3.6. Enbrel (Amgen)
6.3.6.1. Overview
6.3.6.2. Development History
6.3.6.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.6.4. Success Protocol Analysis

6.3.7. HEMLIBRA (Roche)
6.3.7.1. Overview
6.3.7.2. Development History
6.3.7.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.7.4. Success Protocol Analysis

6.3.8. Prolia / Pralia (Amgen)
6.3.8.1. Overview
6.3.8.2. Development History
6.3.8.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.8.4. Success Protocol Analysis

6.3.9. STELARA (Janssen Biotech)
6.3.9.1. Overview
6.3.9.2. Development History
6.3.9.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.9.4. Success Protocol Analysis

6.3.10. Trulicity (Eli Lilly)
6.3.10.1. Overview
6.3.10.2. Development History
6.3.10.3. Phase of Development, Route of Administration, and Target Disease Indication(s)
6.3.10.4. Success Protocol Analysis

6.4. Conclusion

7. SUBCUTANEOUS FORMULATION TECHNOLOGIES: CURRENT MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Need for Subcutaneous Formulation Technologies
7.3. Subcutaneous Formulation Technologies: List of Technologies
7.3.1. Analysis by Fundamental Principle of Technology
7.3.2. Analysis by Type of Molecule
7.3.3. Analysis by Route of Administration
7.3.4. Analysis by Therapeutic Area
7.3.5. Analysis by Advantage(s) Offered

7.4. Subcutaneous Formulation Technologies: List of Developers
7.4.1. Analysis by Year of Establishment
7.4.2. Analysis by Company Size
7.4.3. Analysis by Location of Headquarters
7.4.4. Leading Subcutaneous Formulation Technology: Analysis by Number of Advantages Offered

8. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Assumption and Key Parameters
8.3. Methodology
8.4. Benchmarking of Technology Strength
8.5. Benchmarking of Partnership Activity

8.6. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis
8.6.1. Developers based in North America
8.6.2. Developers based in Europe and Asia

9. SUBCUTANEOUS FORMULATION TECHNOLOGY DEVELOPERS: COMPANY PROFILES
9.1. Chapter Overview
9.2. Adocia
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Technology Overview
9.2.3.1. Biochaperonen Technology
9.2.4. Drug Portfolio
9.2.5. Recent Developments and Future Outlook

9.3. Ajinomoto Bio-Pharma Services
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Technology Overview
9.3.3.1. Crystalomics Formulation Technology
9.3.4. Drug Portfolio
9.3.5. Recent Developments and Future Outlook

9.4. Alteogen
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Technology Overview
9.4.3.1. Hybrozyme Technology
9.4.4. Drug Portfolio
9.4.5. Recent Developments and Future Outlook

9.5. Arecor
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Technology Overview
9.5.3.1. Arestat Technology
9.5.4. Drug Portfolio
9.5.5. Recent Developments and Future Outlook

9.6. Ascendis Pharma
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Technology Overview
9.6.3.1. TransCon Technology
9.6.4. Drug Portfolio
9.6.5. Recent Developments and Future Outlook

9.7. Avadel Pharmaceuticals
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Technology Overview
9.7.3.1. Medusa Technology
9.7.4. Drug Portfolio
9.7.5. Recent Developments and Future Outlook

9.8. Camurus
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Technology Overview
9.8.3.1. FluidCrystal Injection Depot Technology
9.8.4. Drug Portfolio
9.8.5. Recent Developments and Future Outlook

9.9. Creative Biolabs
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Technology Overview
9.9.3.1. Long-Acting Injectable Technology
9.9.4. Drug Portfolio
9.9.5. Recent Developments and Future Outlook

9.10. Creative BioMart
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Technology Overview
9.10.3.1. High Concentration Formulation Technology
9.10.4. Drug Portfolio
9.10.5. Recent Developments and Future Outlook

9.11. DURECT
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Technology Overview
9.11.3.1. SABER Platform
9.11.3.2. CLOUD Platform
9.11.4. Drug Portfolio
9.11.5. Recent Developments and Future Outlook

9.12. Eagle Pharmaceuticals
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Technology Overview
9.12.3.1. Unnamed Technology
9.12.4. Drug Portfolio
9.12.5. Recent Developments and Future Outlook

9.13. Halozyme Therapeutics
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Technology Overview
9.13.3.1. ENHANZE Technology
9.13.4. Drug Portfolio
9.13.5. Recent Developments and Future Outlook

9.14. MedinCell
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Technology Overview
9.14.3.1. BEPO Technology
9.14.4. Drug Portfolio
9.14.5. Recent Developments and Future Outlook

9.15. Serina Therapeutics
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Technology Overview
9.15.3.1. POZ Drug Delivery Technology
9.15.4. Drug Portfolio
9.15.5. Recent Developments and Future Outlook

9.16. Xeris Pharmaceuticals
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Technology Overview
9.16.3.1. XeriJect Technology
9.16.3.2. XeriSol Technology
9.16.4. Drug Portfolio
9.16.5. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Subcutaneous Formulation Technology Developers: List of Partnerships
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Type of Partner
10.3.4. Analysis by Therapeutic Area
10.3.5. Analysis by Focus Area
10.3.6. Analysis by Region
10.3.6.1. Country-wise Distribution
10.3.6.2. Intercontinental and Intracontinental Distribution

10.3.7. Most Active Developers: Analysis by Number of Partnerships

11. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: CURRENT MARKET LANDSCAPE
11.1. Chapter Overview
11.2. Different Types of Subcutaneous Drug Delivery Systems

11.2.1. Large Volume Wearable Injectors
11.2.1.1. Current Market Landscape of Devices for Non-insulin Drugs
11.2.1.1.1. Analysis by Phase of Development
11.2.1.1.2. Analysis by Type of Device
11.2.1.1.3. Analysis by Actuation Mechanism
11.2.1.1.4. Analysis by Technology Used
11.2.1.1.5. Analysis by Route of Administration
11.2.1.1.6. Analysis by Method of Administration
11.2.1.1.7. Analysis by Therapeutic Area
11.2.1.1.8. Analysis by Type of Dose
11.2.1.1.9. Analysis by Storage Volume / Capacity
11.2.1.1.10. Analysis by Usability
11.2.1.1.11. Analysis by Availability of Prefilled Drug Reservoir
11.2.1.1.12. Analysis by Availability of Connectivity
11.2.1.1.13. Analysis by Availability of Drug Compatibility
11.2.1.1.14. Analysis by Availability of Drug Container
11.2.1.1.15. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Non-insulin Drugs

11.2.1.2. Current Market Landscape of Devices for Insulin Drugs
11.2.1.2.1. Analysis by Phase of Development
11.2.1.2.2. Analysis by Type of Device
11.2.1.2.3. Analysis by Type of Dose
11.2.1.2.4. Analysis by Storage Volume / Capacity
11.2.1.2.5. Analysis by Usability
11.2.1.2.6. Analysis by Combination Insulin
11.2.1.2.7. Analysis by Non-Interoperable Device
11.2.1.2.8. Analysis by Availability of Prefilled Drug Reservoir
11.2.1.2.9. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
11.2.1.2.10. Analysis by Availability of Automated Insulin Delivery (AID) Feature
11.2.1.2.11. Analysis by Automatic Insulin Delivery (AID) / Artificial Pancreas
11.2.1.2.12. Analysis by Availability of Connectivity
11.2.1.2.13. Analysis by Availability of Device Control Features
11.2.1.2.14. Most Active Players: Analysis by Number of Large Volume Wearable Injectors for Insulin Drugs

11.2.1.3. Current Market Landscape of Drug Device Combination Products
11.2.1.3.1. Analysis by Phase of Development
11.2.1.3.2. Analysis by Type of Device
11.2.1.3.3. Analysis by Mechanism of Action
11.2.1.3.4. Analysis by Technology Used
11.2.1.3.5. Analysis by Route of Administration
11.2.1.3.6. Analysis by Method of Administration
11.2.1.3.7. Analysis by Therapeutic Area
11.2.1.3.8. Analysis by Type of Dose
11.2.1.3.9. Analysis by Storage Volume / Capacity
11.2.1.3.10. Analysis by Usability
11.2.1.3.11. Analysis by Drug Compatibility
11.2.1.3.12. Analysis by Drug Container
11.2.1.3.13. Most Active Players: Analysis by Number of Products Manufactured

11.2.2. Autoinjectors
11.2.2.1. Current Market Landscape
11.2.2.1.1. Analysis by Actuation Mechanism
11.2.2.1.2. Analysis by Route of Administration
11.2.2.1.3. Analysis by Type of Dose
11.2.2.1.4. Analysis by Storage Volume / Capacity
11.2.2.1.5. Analysis by Usability
11.2.2.1.6. Analysis by Type of Primary Container
11.2.2.1.7. Analysis by Type of Feedback Mechanisms
11.2.2.1.8. Most Active Players: Analysis by Number of Devices

11.2.3. Pen Injectors
11.2.3.1. Current Market Landscape
11.2.3.1.1. Analysis by Type of Dose
11.2.3.1.2. Analysis by Storage Volume / Capacity
11.2.3.1.3. Analysis by Usability
11.2.3.1.4. Most Active Players: Analysis by Number of Devices
11.2.3.2. Drug Device Combination Products

11.2.4. Needle-Free Injection Systems
11.2.4.1. Current Market Landscape
11.2.4.1.1. Analysis by Phase of Development
11.2.4.1.2. Analysis by Actuation Mechanism
11.2.4.1.3. Analysis by Therapeutic Area
11.2.4.1.4. Analysis by Usability
11.2.4.1.5. Most Active Players: Analysis by Number of Devices
11.2.4.2. Drug Device Combination Products

11.2.5. Novel Drug Reconstitution Delivery Systems
11.2.5.1. Current Market Landscape
11.2.5.1.1. Analysis by Volume of Container
11.2.5.1.1. Analysis by Usability
11.2.5.1.2 Analysis by Type of Device
11.2.5.1.3. Analysis by Type of Chamber
11.2.5.1.1. Analysis by Physical State of Drugs
11.2.5.1.4. Analysis by Container Fabrication Material
11.2.5.1.7. Most Active Players: Analysis by Number of Devices

11.2.6. Prefilled Syringes
11.2.6.1. Current Market Landscape
11.2.6.1.1. Analysis by Storage Volume / Capacity
11.2.6.1.2. Analysis by Barrel Fabrication Material
11.2.6.1.3. Analysis by Number of Barrel Chambers
11.2.6.1.4. Analysis by Type of Needle System
11.2.6.1 5. Most Active Players: Analysis by Number of Devices
11.2.6.2. Drug Device Combination Products

11.2.7. Implants
11.2.7.1. Current Market Landscape
11.2.7.1.1. Analysis by Phase of Development
11.2.7.1.2. Analysis by Therapeutic Area
11.2.7.1.3. Analysis by Implant Material
11.2.7.1.4. Analysis by Treatment Duration
11.2.7.1.5. Analysis by Type of Delivery System
11.2.7.1.6. Most Active Players: Analysis by Number of Devices
11.2.7.2. Subcutaneous Implants Eluting Small Molecules

12. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: PRODUCT COMPETITIVENESS
12.1. Large Volume Wearable Injectors
12.1.1. Methodology and Key Parameters
12.1.2. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
12.1.3. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
12.1.4. Product Competitiveness Analysis: Drug Device Combination Products

12.2. Autoinjectors
12.2.1. Methodology and Key Parameters
12.2.1. Product Competitiveness Analysis: Disposable Autoinjectors
12.2.2. Product Competitiveness Analysis: Reusable Autoinjectors

12.3. Needle-Free Injection Systems
12.3.1. Methodology and Key Parameters
12.3.2. Product Competitiveness Analysis: Spring-Based Needle-Free Injection Systems
12.3.3. Product Competitiveness Analysis: Gas-Powered Needle-Free Injection Systems

12.4. Prefilled Syringes
12.4.1. Methodology and Key Parameters
12.4.2. Product Competitiveness Analysis: Glass Barrel Syringes
12.4.3. Product Competitiveness Analysis: Plastic Barrel Syringes

13. APPORVED SUBCUTANEOUS BIOLOGICS: MARKET FORECAST
13.1. Chapter Overview
13.2. Scope and Limitations
13.3. Forecast Methodology and Key Assumptions
13.4. Global Approved Subcutaneous Biologics Market, 2022-2035
13.4.1. Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
13.4.1.1. Approved Subcutaneous Biologics Market for Antibodies, 2022-2035
13.4.1.2. Approved Subcutaneous Biologics Market for Nucleotides, 2022-2035
13.4.1.3. Approved Subcutaneous Biologics Market for Proteins, 2022-2035
13.4.1.4. Approved Subcutaneous Biologics Market for Vaccines, 2022-2035
13.4.1.5. Approved Subcutaneous Biologics Market for Other Biologics, 2022-2035

13.4.2. Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
13.4.2.1. Approved Subcutaneous Biologics Market for Monotherapies, 2022-2035
13.4.2.2. Approved Subcutaneous Biologics Market for Combination Therapies, 2022-2035
13.4.2.3. Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, 2022-2035

13.4.3. Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
13.4.3.1. Approved Subcutaneous Biologics Market for Autoimmune Disorders, 2022-2035
13.4.3.2. Approved Subcutaneous Biologics Market for Blood Disorders, 2022-2035
13.4.3.3. Approved Subcutaneous Biologics Market for Bone Disorders, 2022-2035
13.4.3.4. Approved Subcutaneous Biologics Market for Cardiovascular Disorders, 2022-2035
13.4.3.5. Approved Subcutaneous Biologics Market for Genetic Disorders, 2022-2035
13.4.3.6. Approved Subcutaneous Biologics Market for Hormonal Disorders, 2022-2035
13.4.3.7. Approved Subcutaneous Biologics Market for Infectious Disorders, 2022-2035
13.4.3.8. Approved Subcutaneous Biologics Market for Inflammatory Disorders, 2022-2035
13.4.3.9. Approved Subcutaneous Biologics Market for Metabolic Disorders, 2022-2035
13.4.3.10. Approved Subcutaneous Biologics Market for Neurological Disorders, 2022-2035
13.4.3.11. Approved Subcutaneous Biologics Market for Oncological Disorders, 2022-2035
13.4.3.12. Approved Subcutaneous Biologics Market for Respiratory Disorders, 2022-2035
13.4.3.13. Approved Subcutaneous Biologics Market for Women’s Health Disorders, 2022- 2035
13.4.3.17. Approved Subcutaneous Biologics Market for Other Disorders, 2022-2035

13.4.4. Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
13.4.4.1. Approved Subcutaneous Biologics Market in North America, 2022-2035
13.4.4.2. Approved Subcutaneous Biologics Market in Europe, 2022-2035
13.4.4.3. Approved Subcutaneous Biologics Market in Asia, 2022-2035
13.4.4.4. Approved Subcutaneous Biologics Market in Middle East and North Africa, 2022- 2035
13.4.4.5. Approved Subcutaneous Biologics Market in Latin America, 2022-2035
13.4.4.6. Approved Subcutaneous Biologics Market in Rest of the World, 2022-2035

13.4.5. Drug-wise Sales Forecast
13.4.5.1. AIMOVIG (erenumab-aooe), Amgen
13.4.5.1.1 Sales Forecast

13.4.5.2. AJOVY (fremanezumab-vfrm), Teva Pharmaceuticals
13.4.5.2.1 Sales Forecast

13.4.5.3. Apidra (insulin glulisine), Sanofi
13.4.5.3.1. Sales Forecast

13.4.5.4. Basaglar / Abrasia (EU) (insulin glargine injection), Eli Lilly
13.4.5.4.1. Sales Forecast

13.4.5.5. BENLYSTA (belimumab), Human Genome Sciences
13.4.5.5.1. Sales Forecast

13.4.5.6. BESREMi (ropeginterferon alfa-2b-njft), PharmaEssentia
13.4.5.6.1. Sales Forecast

13.4.5.7. BIOTHRAX (Anthrax Vaccine Adsorbed), Emergent Biosolutions
13.4.5.7.1. Sales Forecast

13.4.5.8. CABLIVI (Caplacizumab), Abylnx
13.4.5.8.1. Sales Forecast

13.4.5.9. Cegfila, Mundipharma Corporation
13.4.5.9.1. Sales Forecast

13.4.5.10. CIMZIA (certolizumab pegol), UCB
13.4.5.10.1. Sales Forecast

13.4.5.11. COSENTYX (secukinumab), Novartis
13.4.5.11.1. Sales Forecast

13.4.5.12. CRYSVITA (burosumab-twza), Ultragenyx
13.4.5.12.1. Sales Forecast

13.4.5.13. Cuvitru (immune globulin subcutaneous [human], 20% solution), Shire
13.4.5.13.1. Sales Forecast

13.4.5.14. DARZALEX FASPRO (daratumumab and hyaluronidase-fihj / DARZALEX SC, Halozyme
13.4.5.14.1. Sales Forecast

13.4.5.15. DENGVAXIA (Dengue Tetravalent Vaccine), Sanofi Pasteur
13.4.5.15.1. Sales Forecast

13.4.5.16. DUPIXENT (dupilumab), Regeneron Pharmaceuticals
13.4.5.16.1. Sales Forecast

13.4.5.17. EMGALITY (galcanezumab-gnlm), Eli Lilly
13.4.5.17.1. Sales Forecast

13.4.5.18. EMPAVELI (pegcetacoplan), Apellis Pharmaceuticals
13.4.5.18.1. Sales Forecast

13.4.5.19. Enbrel (etanercept), Amgen
13.4.5.19.1. Sales Forecast

13.4.5.20. ENSPRYNG (satralizumab), Genentech
13.4.5.20.1. Sales Forecast

13.4.5.21. EVENITY (romosozumab-aqqg), Amgen
13.4.5.21.1. Sales Forecast

13.4.5.22. FASENRA (benralizumab), AstraZeneca
13.4.5.22.1. Sales Forecast

13.4.5.23. FIASP (Insulin Aspart), Novo Nordisk
13.4.5.23.1. Sales Forecast

13.4.5.24. Fulphila (pegfilgrastim-jmdb), Mylan Pharmaceuticals
13.4.5.24.1. Sales Forecast

13.4.5.25. Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified), Grifols Therapeutics
13.4.5.25.1. Sales Forecast

13.4.5.26. GATTEX / Revestive (teduglutide [rDNA origin]), NPS Pharmaceuticals
13.4.5.26.1. Sales Forecast

13.4.5.27. GIVLAARI (givosiran), Alnylam Pharmaceuticals
13.4.5.27.1. Sales Forecast

13.4.5.28. HAEGARDA, CSL Behring
13.4.5.28.1. Sales Forecast

13.4.5.29. HEMLIBRA (emicizumab-kxwh), Roche
13.4.5.29.1. Sales Forecast

13.4.5.30. Hepcludex (Bulevirtide), Gilead Sciences
13.4.5.30.1. Sales Forecast

13.4.5.31. Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid), CSL Behring
13.4.5.31.1. Sales Forecast

13.4.5.32. HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase), Baxalta
13.4.5.32.1. Sales Forecast

13.4.5.33. ILARIS (canakinumab), Novartis
13.4.5.33.1. Sales Forecast

13.4.5.34. ILUMYA (tildrakizumab-asmn) / Ilumetri, Sun Pharma
13.4.5.34.1. Sales Forecast

13.4.5.35. Kalbitor (ecallantide), Dyax
13.4.5.35.1. Sales Forecast

13.4.5.36. Kesimpta (ofatumumab), Novartis
13.4.5.36.1. Sales Forecast

13.4.5.37. KEVZARA (sarilumab), Regeneron Pharmaceuticals
13.4.5.37.1. Sales Forecast

13.4.5.38. KINERET (anakinra), Swedish Orphan Biovitrum
13.4.5.38.1. Sales Forecast

13.4.5.39. Kyntheum / SILIQ / Lumicef (brodalumab), AstraZeneca
13.4.5.39.1. Sales Forecast

13.4.5.40. Leqvio (Inclisiran), Alnylam Pharmaceuticals
13.4.5.40.1. Sales Forecast

13.4.5.41. Lonquex (lipegfilgrastim), Teva Pharmaceuticals
13.4.5.41.1. Sales Forecast

13.4.5.42. Lyumjev (insulin lispro-aabc), Eli Lilly
13.4.5.42.1. Sales Forecast

13.4.5.43. Norditropin (somatropin), Novo Nordisk
13.4.5.43.1. Sales Forecast

13.4.5.44. NPLATE (romiplostim), Amgen
13.4.5.44.1. Sales Forecast

13.4.5.45. Nucala (mepolizumab), GlaxoSmithKline
13.4.5.45.1. Sales Forecast

13.4.5.46. OXLUMO (lumasiran), Alnylam Pharmaceuticals
13.4.5.46.1. Sales Forecast

13.4.5.47. PALYNZIQ (pegvaliase-pqpz), BioMarin Pharmaceutical
13.4.5.47.1. Sales Forecast

13.4.5.48. Pergoveris (follitropin alfa / lutropin alfa), Merck
13.4.5.48.1. Sales Forecast

13.4.5.49. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf), Roche
13.4.5.49.1. Sales Forecast

13.4.5.50. PRALUENT (alirocumab), Regeneron Pharmaceuticals
13.4.5.50.1. Sales Forecast

13.4.5.51. Prolia / Pralia (denosumab), Amgen
13.4.5.51.1. Sales Forecast

13.4.5.52. REBLOZYL (luspatercept-aamt), Acceleron Pharma
13.4.5.52.1. Sales Forecast

13.4.5.53. REKOVELLE (follitropin delta), Ferring Pharmaceuticals
13.4.5.53.1. Sales Forecast

13.4.5.54. Repatha (evolocumab), Amgen
13.4.5.54.1. Sales Forecast

13.4.5.55. RYZODEG 70/30 (insulin degludec and insulin aspart), Novo Nordisk
13.4.5.55.1. Sales Forecast

13.4.5.56. Skyrizi ( isankizumab), AbbVie
13.4.5.56.1. Sales Forecast

13.4.5.57. SKYTROFA (lonapegsomatropin-tcgd), Ascendis Pharma
13.4.5.57.1. Sales Forecast

13.4.5.58. SOLIQUA 100/33 (insulin glargine & lixisenatide injection), Sanofi
13.4.5.58.1. Sales Forecast

13.4.5.59. STELARA (ustekinumab), Janssen Biotech
13.4.5.59.1. Sales Forecast

13.4.5.60. Strensiq (asfotase alfa), Alexion Pharmaceuticals
13.4.5.60.1. Sales Forecast

13.4.5.61. TAKHZYRO (lanadelumab-flyo), Takeda Pharmaceuticals
13.4.5.61.1. Sales Forecast

13.4.5.62. Taltz (ixekizumab), Eli Lilly
13.4.5.62.1. Sales Forecast

13.4.5.63. TEGSEDI (inotersen), Ionis Pharmaceuticals
13.4.5.63.1. Sales Forecast
 
13.4.5.64. Toujeo (insulin glargine injection) U-300, Sanofi
13.4.5.64.1. Sales Forecast
 
13.4.5.65. TREMFYA (guselkumab), Janssen Biotech
13.4.5.65.1. Sales Forecast
 
13.4.5.66. TRESIBA (insulin degludec injection), Novo Nordisk
13.4.5.66.1. Sales Forecast
 
13.4.5.67. Trulicity (dulaglutide), Eli Lilly
13.4.5.67.1. Sales Forecast

13.4.5.68. TYMLOS (abaloparatide), Radius Health
13.4.5.68.1. Sales Forecast

13.4.5.69. Tysabri (Natalizumab), Biogen
13.4.5.69.1. Sales Forecast

13.4.5.70. Voxzogo (vosoritide), BioMarin Pharmaceutical
13.4.5.70.1. Sales Forecast

13.4.5.71. VYLEESI (bremelanotide injection), AMAG Pharmaceuticals
13.4.5.71.1. Sales Forecast

13.4.5.72. XEMBIFY (immune globulin subcutaneous, human – klhw), Grifols Therapeutics
13.4.5.72.1. Sales Forecast

13.4.5.73. Xgeva / RANMARK (denosumab), Amgen
13.4.5.73.1. Sales Forecast

13.4.5.74. XULTOPHY / IdegLira (insulin degludec and liraglutide injection), Novo Nordisk
13.4.5.74.1. Sales Forecast

13.4.5.75. XYOSTED (testosterone enanthate), Antares Pharma
13.4.5.75.1. Sales Forecast

13.4.5.76. ZEGALOGUE (dasiglucagon), Zealand Pharma
13.4.5.76.1. Sales Forecast

13.3.6. Conclusion

14. SUBCUTANEOUS FORMULATION TECHNOLOGIES: MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Subcutaneous Formulation Technologies Market, 2022-2035
14.3.1. Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022 and 2035
14.3.1.1. Subcutaneous Formulation Technologies Market for Milestone Payments, 2022- 2035

14.3.1.2. Subcutaneous Formulation Technologies Market for Upfront Payments, 2022-2035

14.3.2. Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022 and 2035
14.3.2.1. Subcutaneous Formulation Technologies Market for Amino Acid Interaction Principles, 2022-2035
14.3.2.2. Subcutaneous Formulation Technologies Market for Complex Formation Principles, 2022-2035
14.3.2.3. Subcutaneous Formulation Technologies Market for Encapsulation Principles, 2022-2035
14.3.2.4. Subcutaneous Formulation Technologies Market for Other Fundamental Principles, 2022-2035

14.3.3. Subcutaneous Formulation Technologies Market: Distribution by End User, 2022 and 2035
14.3.3.1. Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, 2022-2035
14.3.3.2. Subcutaneous Formulation Technologies Market for Biotechnology Companies, 2022-2035
14.3.3.3. Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, 2022-2035
14.3.3.4. Subcutaneous Formulation Technologies Market for Educational Institutes, 2022-2035
14.3.3.5. Subcutaneous Formulation Technologies Market for Investors, 2022-2035
14.3.3.6. Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, 2022-2035
14.3.3.7. Subcutaneous Formulation Technologies Market for Research Institutes, 2022-2035
14.3.3.8. Subcutaneous Formulation Technologies Market for Other End Users, 2022-2035

14.3.4. Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
14.3.4.1. Subcutaneous Formulation Technologies Market for Autoimmune Disorders, 2022-2035
14.3.4.2. Subcutaneous Formulation Technologies Market for Genetic Disorders, 2022-2035
14.3.4.3. Subcutaneous Formulation Technologies Market for Infectious Disorders, 2022-2035
14.3.4.4. Subcutaneous Formulation Technologies Market for Metabolic Disorders, 2022-2035
14.3.4.5. Subcutaneous Formulation Technologies Market for Oncological Disorders, 2022-2035
14.3.4.6. Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, 2022-2035
14.3.4.7. Subcutaneous Formulation Technologies Market for Other Disorders, 2022-2035

14.3.5. Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
14.3.5.1. Subcutaneous Formulation Technologies Market in North America, 2022-2035
14.3.5.2. Subcutaneous Formulation Technologies Market in Europe, 2022-2035
14.3.5.3. Subcutaneous Formulation Technologies Market in Asia, 2022-2035

14.3.6. Conclusion

15. SUBCUTANEOUS DRUG DELIVERY SYSTEMS: MARKET FORECAST
15.1. Subcutaneous Drug Delivery Systems Market
15.2. Drug Delivery System 1: Large Volume Wearable Injectors
15.2.1. Forecast Methodology and Key Assumptions
15.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Value)
15.2.2.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Value)
15.2.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Value)
15.2.2.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Value)
15.2.2.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Value)
15.2.2.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Value)
15.2.2.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe:
 Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Value)
15.2.2.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Value)
15.2.2.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Value)
15.2.2.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Value)
15.2.2.7.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Value)

15.2.2.7.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Value)

15.2.2.7.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America:
 Distribution by Therapeutic Area, 2021-2035 (By Value)

15.2.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Value)
15.2.2.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
15.2.2.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
15.2.2.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Value)
15.2.2.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Value)
15.2.2.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Value)
15.2.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (By Volume)
15.2.3.1. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.2. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (By Volume)
15.2.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (By Volume)
15.2.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021-2035 (By Volume)
15.2.3.5.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.5.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.5.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (By Volume)
15.2.3.6.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.6.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.6.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (By Volume)
15.2.3.7.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.7.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.7.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (By Volume)
15.2.3.8.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (By Volume)
15.2.3.8.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (By Volume)
15.2.3.8.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (By Volume)

15.2.4. Global Large Volume Wearable Injectors Market for Insulin, 2021-2035
15.2.4.1. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035
15.2.4.2. Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035
15.2.4.3. Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035 (By Value)
15.2.4.3.1. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035
15.2.4.3.2. Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035

15.2.4.4. Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035
15.2.4.4.1. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035
15.2.4.4.2. Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035

15.2.4.5. Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035
15.2.4.5.1. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035
15.2.4.5.2. Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035

15.2.4.6. Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035
15.2.4.6.1. Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035
15.2.4.6.2. Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035

15.2.4.7. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035
15.2.4.7.1. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035
15.2.4.7.2. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035

15.3. Drug Delivery System 2: Autoinjectors
15.3.1. Forecast Methodology and Key Assumptions
15.3.2. Global Autoinjectors Market, 2021-2035 (By Value)
15.3.2.1. Global Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
15.3.2.1.1. Global Autoinjectors Market for Anaphylaxis: Distribution by Usability, 2021-2035 (By Value)
15.3.2.1.1.1. Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)

15.3.2.1.2. Global Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.1.2.1. Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)
15.3.2.1.2.2. Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021- 2035 (By Value)

15.3.2.1.3. Global Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.1.3.1. Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (By Value)

15.3.2.1.4. Global Autoinjectors Market for Anaphylaxis: Distribution by Geography, 2021-2035 (By Value)
15.3.2.1.4.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (By Value)
15.3.2.1.4.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (By Value)
15.3.2.1.4.3. Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (By Value)
15.3.2.1.4.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (By Value)

15.3.2.2. Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.1. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Usability, 2021- 2035 (By Value)
15.3.2.2.1.1. Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.1.2. Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)

15.3.2.2.2. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.2.2.1. Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.2.2. Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)

15.3.2.2.3. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.2.3.1. Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.3.2. Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)
15.3.2.2.3.3. Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Value)

15.3.2.2.4. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Geography, 2021-2035 (By Value)
15.3.2.2.4.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (By Value)
15.3.2.2.4.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (By Value)
15.3.2.2.4.3. Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (By Value)
15.3.2.2.4.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (By Value)

15.3.2.3. Global Autoinjectors Market for Migraine, 2021-2035 (By Value)
15.3.2.3.1. Global Autoinjectors Market for Migraine: Distribution by Usability, 2021-2035 (By Value)
15.3.2.3.1.1. Global Disposable Autoinjectors Market for Migraine, 2021-2035 (By Value)

15.3.2.3.2. Global Autoinjectors Market for Migraine: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.3.2.1. Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (By Value)

15.3.2.3.3. Global Autoinjectors Market for Migraine: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.3.3.1. Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (By Value)
15.3.2.3.3.2. Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (By Value)

15.3.2.3.4. Global Autoinjectors Market for Migraine: Distribution by Geography, 2021-2035 (By Value)
15.3.2.3.4.1. Autoinjectors Market for Migraine in North America, 2021-2035 (By Value)
15.3.2.3.4.2. Autoinjectors Market for Migraine in Europe, 2021-2035 (By Value)
15.3.2.3.4.3. Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (By Value)
15.3.2.3.4.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (By Value)

15.3.2.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.1. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Usability, 2021-2035 (By Value)
15.3.2.4.1.1. Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.1.2. Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)

15.3.2.4.2. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.4.2.1. Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.2.2. Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)

15.3.2.4.3. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.4.3.1. Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.3.2. Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)
15.3.2.4.3.3. Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Value)

15.3.2.4.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Geography, 2021-2035 (By Value)
15.3.2.4.4.1. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (By Value)
15.3.2.4.4.2. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (By Value)
15.3.2.4.4.3. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (By Value)
15.3.2.4.4.4. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (By Value)

15.3.2.5. Global Autoinjectors Market for Diabetes, 2021-2035 (By Value)
15.3.2.5.1. Global Autoinjectors Market for Diabetes: Distribution by Usability, 2021-2035 (By Value)
15.3.2.5.1.1. Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (By Value)

15.3.2.5.2. Global Autoinjectors Market for Diabetes: Distribution by Route of Administration, 2021-2035 (By Value)
1.3.2.5.2.1. Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (By Value)

15.3.2.5.3. Global Autoinjectors Market for Diabetes: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.5.3.1. Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (By Value)
15.3.2.5.3.2. Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (By Value)

15.3.2.5.4. Global Autoinjectors Market for Diabetes: Distribution by Geography, 2021-2035 (By Value)
15.3.2.5.4.1. Autoinjectors Market for Diabetes in North America, 2021-2035 (By Value)
15.3.2.5.4.2. Autoinjectors Market for Diabetes in Europe, 2021-2035 (By Value)
15.3.2.5.4.3. Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (By Value)
15.3.2.5.4.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (By Value)

15.3.2.6. Global Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.1. Global Autoinjectors Market for Other Indications: Distribution by Usability, 2021-2035 (By Value)
15.3.2.6.1.1. Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (By Value)

15.3.2.6.2. Global Autoinjectors Market for Other Indications: Distribution by Route of Administration, 2021-2035 (By Value)
15.3.2.6.2.1. Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.2.2. Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.2.3. Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Value)

15.3.2.6.3. Global Autoinjectors Market for Other Indications: Distribution by Type of Molecule, 2021-2035 (By Value)
15.3.2.6.3.1. Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.3.2. Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)
15.3.2.6.3.3. Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (By Value)

15.3.2.6.4. Global Autoinjectors Market for Other Indications: Distribution by Geography, 2021-2035 (By Value)
15.3.2.6.4.1. Autoinjectors Market for Other Indications in North America, 2021-2035 (By Value)
15.3.2.6.4.2. Autoinjectors Market for Other Indications in Europe, 2021-2035 (By Value)
15.3.2.6.4.3. Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (By Value)
15.3.2.6.4.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (By Value)

15.3.3. Global Autoinjectors Market, 2021-2035 (By Volume)
15.3.3.1. Global Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
15.3.3.1.1. Global Autoinjectors Market for Anaphylaxis: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.1.1.1. Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)

15.3.3.1.2. Global Autoinjectors Market for Anaphylaxis: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.1.2.1. Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)
15.3.3.1.2.2. Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)

15.3.3.1.3. Global Autoinjectors Market for Anaphylaxis: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.1.3.1. Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (By Volume)

15.3.3.1.4. Global Autoinjectors Market for Anaphylaxis: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.1.4.1. Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (By Volume)
15.3.3.1.4.2. Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (By Volume)
15.3.3.1.4.3. Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.1.4.4. Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (By Volume)

15.3.3.2. Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.1. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.2.1.1. Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.1.2. Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)

15.3.3.2.2. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.2.2.1. Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.2.2. Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)

15.3.3.2.3. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.2.3.1. Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.3.2. Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)
15.3.3.2.3.3. Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (By Volume)

15.3.3.2.4. Global Autoinjectors Market for Multiple Sclerosis: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.2.4.1. Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (By Volume)
15.3.3.2.4.2. Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (By Volume)
15.3.3.2.4.3. Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.2.4.4. Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (By Volume)

15.3.3.3. Global Autoinjectors Market for Migraine, 2021-2035 (By Volume)
15.3.3.3.1. Global Autoinjectors Market for Migraine: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.3.1.1. Global Disposable Autoinjectors Market for Migraine, 2021-2035 (By Volume)

15.3.3.3.2. Global Autoinjectors Market for Migraine: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.3.2.1. Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (By Volume)

15.3.3.3.3. Global Autoinjectors Market for Migraine: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.3.3.1. Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (By Volume)
15.3.3.3.3.2. Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (By Volume)
15.3.3.3.4. Global Autoinjectors Market for Migraine: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.3.4.1. Autoinjectors Market for Migraine in North America, 2021-2035 (By Volume)
15.3.3.3.4.2. Autoinjectors Market for Migraine in Europe, 2021-2035 (By Volume)
15.3.3.3.4.3. Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.3.4.4. Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (By Volume)

15.3.3.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.1. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.4.1.1. Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.1.2. Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)

15.3.3.4.2. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.4.2.1. Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.2.2. Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)

15.3.3.4.3. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.4.3.1. Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.3.2. Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.3.3. Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (By Volume)
15.3.3.4.4. Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.4.4.1. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (By Volume)
15.3.3.4.4.2. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (By Volume)
15.3.3.4.4.3. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.4.4.4. Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (By Volume)

15.3.3.5. Global Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
15.3.3.5.1. Global Autoinjectors Market for Diabetes: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.5.1.1. Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (By Volume)

15.3.3.5.2. Global Autoinjectors Market for Diabetes: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.5.2.1. Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (By Volume)

15.3.3.5.3. Global Autoinjectors Market for Diabetes: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.5.3.1. Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (By Volume)
15.3.3.5.3.2. Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (By Volume)

15.3.3.5.4. Global Autoinjectors Market for Diabetes: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.5.4.1. Autoinjectors Market for Diabetes in North America, 2021-2035 (By Volume)
15.3.3.5.4.2. Autoinjectors Market for Diabetes in Europe, 2021-2035 (By Volume)
15.3.3.5.4.3. Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.5.4.4. Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (By Volume)

15.3.3.6. Global Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.1. Global Autoinjectors Market for Other Indications: Distribution by Usability, 2021-2035 (By Volume)
15.3.3.6.1.1. Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (By Volume)

15.3.3.6.2. Global Autoinjectors Market for Other Indications: Distribution by Route of Administration, 2021-2035 (By Volume)
15.3.3.6.2.1. Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.2.2. Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.2.3. Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (By Volume)

15.3.3.6.3. Global Autoinjectors Market for Other Indications: Distribution by Type of Molecule, 2021-2035 (By Volume)
15.3.3.6.3.1. Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.3.2. Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)
15.3.3.6.3.3. Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (By Volume)

15.3.3.6.4. Global Autoinjectors Market for Other Indications: Distribution by Geography, 2021-2035 (By Volume)
15.3.3.6.4.1. Autoinjectors Market for Other Indications in North America, 2021-2035 (By Volume)
15.3.3.6.4.2. Autoinjectors Market for Other Indications in Europe, 2021-2035 (By Volume)
15.3.3.6.4.3. Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (By Volume)
15.3.3.6.4.4. Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (By Volume)

15.4. Drug Delivery System 3: Prefilled Syringes
15.4.1. Forecast Methodology and Key Assumptions
15.4.2. Global Prefilled Syringes Market, 2020-2030
15.4.2.1. Global Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020-2030
15.4.2.2. Global Prefilled Syringes Market: Distribution by Type of Chamber System, 2020-2030
15.4.2.3. Global Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020-2030
15.4.2.4. Global Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030

15.5. Drug Delivery System 4: Needle-Free Injection Systems
15.5.1. Forecast Methodology and Key Assumptions
15.5.2. Global Needle-Free Injection Systems Market, 2020-2030
15.5.2.1. Global Needle-Free Injection Systems Market: Distribution by Usability, 2020-2030
15.5.2.2. Global Needle-Free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030
15.5.2.3. Global Needle-Free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030

15.6. Drug Delivery System 5: Novel Drug Reconstitution Systems
15.6.1. Forecast Methodology and Key Assumptions
15.6.2. Global Novel Drug Reconstitution Systems Market, 2021-2030
15.6.2.1. Global Dual Chamber Prefilled Syringes Market, 2021-2030
15.6.2.1.1. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Physical State of Drug
15.6.2.1.1.1. Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030
15.6.2.1.1.2. Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030
15.6.2.1.2. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Type of Fabrication Material Used
15.6.2.1.2.1. Glass Dual Chamber Prefilled Syringes Market, 2021-2030
15.6.2.1.2.2. Plastic Dual Chamber Prefilled Syringes Market, 2021-2030

15.6.2.1.3. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
15.6.2.1.3.1. Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030
15.6.2.1.3.2. Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030
15.6.2.1.3.3. Dual Chamber Prefilled Syringes Market for 2.6-5 mL Syringes, 2021-2030
15.6.2.1.3.4. Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030

15.6.2.1.4. Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Geography
15.6.2.1.4.1. Dual Chamber Prefilled Syringes Market in North America, 2021-2030
15.6.2.1.4.2. Dual Chamber Prefilled Syringes Market in Europe, 2021-2030
15.6.2.1.4.3. Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030
15.6.2.1.4.4. Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030
15.6.2.1.4.5. Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030

15.6.2.2. Global Dual Chamber Cartridges Market, 2021-2030
15.6.2.2.1. Dual Chamber Cartridges Market, 2021-2030: Distribution by Physical State of Drug
15.6.2.2.1.1. Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030
15.6.2.2.1.2. Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030

15.6.2.2.2. Dual Chamber Cartridges Market, 2021-2030: Distribution by Type of Fabrication Material Used
15.6.2.2.2.1. Glass Dual Chamber Cartridges Market, 2021-2030
15.6.2.2.2.2. Plastic Dual Chamber Cartridges Market, 2021-2030

15.6.2.2.3. Dual Chamber Cartridges Market, 2021-2030: Distribution by Volume
15.6.2.2.3.1. Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030
15.6.2.2.3.2. Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030
15.6.2.2.3.3. Dual Chamber Cartridges Market for 2.6-5 mL Cartridges, 2021-2030
15.6.2.2.3.4. Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030

15.6.2.2.4. Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
15.6.2.2.4.1. Dual Chamber Cartridges Market in North America, 2021-2030
15.6.2.2.4.2. Dual Chamber Cartridges Market in Europe, 2021-2030
15.6.2.2.4.3. Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030
15.6.2.2.4.4. Dual Chamber Cartridges Market in Latin America, 2021-2030
15.6.2.2.4.5. Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030

15.6.2.3. Global Dual / Multi Chamber Infusion Bags Market, 2021-2030
15.6.2.3.1. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
15.6.2.3.1.1. Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, 2021-2030
15.6.2.3.1.2. Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, 2021-2030

15.6.2.3.2. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
15.6.2.3.2.1. Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate, 2021-2030
15.6.2.3.2.2. Dual / Multi Chamber Infusion Bags Market for Polypropylene, 2021-2030
15.6.2.3.2.3. Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride, 2021-2030
15.6.2.3.2.4. Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials, 2021-2030

15.6.2.3.3. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
15.6.2.3.3.1. Dual / Multi Chamber Infusion Bags Market for <250 mL Infusion Bags, 2021-2030
15.6.2.3.3.2. Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, 2021- 2030
15.6.2.3.3.3. Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Infusion Bags, 2021-2030
15.6.2.3.3.4. Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, 2021-2030

15.6.2.3.4. Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
15.6.2.3.4.1. Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030
15.6.2.3.4.2. Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030
15.6.2.3.4.3. Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030
15.6.2.3.4.4. Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030
14.6.2.3.4.5. Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030

16. SWOT ANALYSIS
16.1. Chapter Overview
16.2. Comparison of SWOT Factors
16.2.1. Strengths
16.2.2. Weaknesses
16.2.3. Opportunities
16.2.4. Threats

17. CONCLUDING REMARKS
17.1. Chapter Overview

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview

18.2. Lindy Biosciences
18.2.1. Company Snapshot
18.2.2. Interview Transcript: Deborah Bitterfield, Chief Executive Officer and Founder

18.3. Oval Medical Technologies
18.3.1. Company Snapshot
18.3.2. Interview Transcript: Matthew Young, Chief Technology Officer and Founder

18.4. Xeris Pharmaceuticals
18.4.1. Company Snapshot
18.4.2. Interview Transcript: Steve Prestrelski, Chief Scientific Officer and Founder; Hong Qi, Vice President, Product Development; and Scott Coleman, Ex Sr. Scientist Formulation)

18.5. DALI Medical Devices
18.5.1. Company Snapshot
18.5.2. Interview Transcript: David Daily, Chief Executive Officer and Co-Founder

18.6. Excelse Bio
18.6.1. Company Snapshot
18.6.2. Interview Transcript: Michael Reilly, Chief Executive Officer and Co-Founder

18.7. i-novion
18.7.1. Company Snapshot
18.7.2. Interview Transcript: Poonam R Velagaleti, Co-Founder

18.8. Enable Injections
18.8.1. Company Snapshot
18.8.2. Interview Transcript: Michael Hooven, Chief Executive Officer

18.9. Immunovaccine Technologies
18.9.1. Company Snapshot
18.9.2. Interview Transcript: Frederic Ors, Ex Chief Executive Officer

18.10. Portal Instruments
18.10.1. Company Snapshot
18.10.2. Interview Transcript: Patrick Anquetil, Chief Executive Officer

18.11. Elcam Medical
18.11.1. Company Snapshot
18.11.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist

18.12. West Pharmaceutical Services
18.12.1. Company Snapshot
18.12.2. Interview Transcript: Tiffany H Burke, Director, Global Communications and Graham Reynolds, Vice President and General Manager, Global Biologics

18.13. MedinCell
18.13.1. Company Snapshot
18.13.2. Interview Transcript: David Heuzé, Communication Leader

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 2.1 Executive Summary: Approved Subcutaneous Biologics Market Landscape
Figure 2.2 Executive Summary: Clinical-stage Subcutaneous Biologics Market Landscape
Figure 2.3 Executive Summary: Executive Summary: Subcutaneous Formulation Technologies Market Landscape
Figure 2.4 Executive Summary: Partnerships and Collaborations
Figure 2.5 Executive Summary: Approved Subcutaneous Biologics Market Forecast
Figure 2.6 Executive Summary: Subcutaneous Formulation Technologies and Drug Delivery Systems Market
Figure 2.1 Executive Summary: Approved Subcutaneous Biologics Market Landscape
Figure 3.1 Types of Biologically Derived Therapeutics
Figure 3.2 Conversion from Intravenous to Subcutaneous Formulation: Key Points for Pharma Companies
Figure 3.3 Process of Developing a Subcutaneous Formulation from Intravenous Product
Figure 3.4 Subcutaneous Drug Delivery: Possible Routes of Administration for Large-Dose Biologics
Figure 3.5 Landscape of Large Volume Subcutaneous Drug Delivery Devices
Figure 3.6 Steps Involved in Subcutaneous Drug Delivery
Figure 4.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Figure 4.2 Approved Subcutaneous Biologics: Distribution by Type of Molecule
Figure 4.3 Approved Subcutaneous Biologics: Distribution by Approval Year and Type of Molecule
Figure 4.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
Figure 4.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
Figure 4.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
Figure 4.7 Approved Subcutaneous Biologics: Distribution by Route of Administration and Method of Administration
Figure 4.8 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 4.9 Approved Subcutaneous Biologics: Distribution by Dose Concentration
Figure 4.10 Approved Subcutaneous Biologics: Distribution by Target Disease(s) Indication Figure 4.11 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
Figure 4.12 Approved Subcutaneous Biologics: Distribution by Approval Year and Therapeutic Area
Figure 4.13 Approved Subcutaneous Biologics: Distribution by Type of Available Formulation
Figure 4.14 Approved Subcutaneous Biologics: Distribution by Route of Administration and Type of Available Formulation
Figure 4.15 Approved Subcutaneous Biologics Developers: Distribution by Year of Establishment
Figure 4.16 Approved Subcutaneous Biologics Developers: Distribution by Company Size
Figure 4.17 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Figure 4.18 Leading Developers: Distribution by Number of Approved Subcutaneous Biologics
Figure 5.1 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
Figure 5.2 Clinical-Stage Subcutaneous Biologics: Distribution by Mechanism of Action
Figure 5.3 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule
Figure 5.4 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
Figure 5.5 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Therapy
Figure 5.6 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
Figure 5.7 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Dosing Frequency
Figure 5.8 Clinical-Stage Subcutaneous Biologics: Distribution by Target Disease Indication(s)
Figure 5.9 Clinical-Stage Subcutaneous Biologics: Distribution by Therapeutic Area
Figure 5.10 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Therapeutic Area
Figure 5.11 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Therapeutic Area
Figure 5.12 Clinical-Stage Subcutaneous Biologics: Distribution by Special Drug Designation(s) Awarded
Figure 5.13 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Year of Establishment
Figure 5.14 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Company Size
Figure 5.15 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Figure 5.16 Leading Developers: Distribution by Number of Clinical-Stage Subcutaneous Biologics
Figure 6.1 Leading Approved Subcutaneous Biologics: Distribution by Value Creation Sales
Figure 6.2 BENLYSTA (Roche): Approval Timeline
Figure 6.3 BENLYSTA (Roche): Success Protocol Analysis
Figure 6.4 BESREMi (PharmaEssentia): Approval Timeline
Figure 6.5 BESREMi (PharmaEssentia): Success Protocol Analysis
Figure 6.6 COSENTYX (Novartis): Approval Timeline
Figure 6.7 COSENTYX (Novartis): Success Protocol Analysis
Figure 6.8 DARZALEX FASPRO (Halozyme): Approval Timeline
Figure 6.9 DARZALEX FASPRO (Halozyme): Success Protocol Analysis
Figure 6.10 DUPIXENT (Regeneron Pharmaceuticals) : Approval Timeline
Figure 6.11 DUPIXENT (Regeneron Pharmaceuticals): Success Protocol Analysis
Figure 6.12 Enbrel (Amgen): Approval Timeline
Figure 6.13 Enbrel (Amgen) : Success Protocol Analysis
Figure 6.14 HEMLIBRA (Roche): Approval Timeline
Figure 6.15 HEMLIBRA (Roche): Success Protocol Analysis
Figure 6.16 Prolia / Pralia (Amgen): Approval Timeline
Figure 6.17 Prolia / Pralia (Amgen): Success Protocol Analysis
Figure 6.18 STELARA (Janssen Biotech): Approval Timeline
Figure 6.19 STELARA (Janssen Biotech): Success Protocol Analysis
Figure 6.20 Trulicity (Eli Lilly): Approval Timeline
Figure 6.21 Trulicity (Eli Lilly): Success Protocol Analysis
Figure 6.22 Success Protocol Analysis: Conclusion
Figure 7.1 Subcutaneous Formulation Technologies: Distribution by Fundamental Principle of Technology
Figure 7.2 Subcutaneous Formulation Technologies: Distribution by Type of Molecule
Figure 7.3 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Figure 7.4 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Route of Administration
Figure 7.5 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
Figure 7.6 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
Figure 7.7 Subcutaneous Formulation Technology Developers: Distribution by Year of Establishment
Figure 7.8 Subcutaneous Formulation Technology Developers: Distribution by Company Size
Figure 7.9 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region-wise)
Figure 7.10 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.11 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region-wise)
Figure 7.12 Subcutaneous Formulation Technologies: Distribution by Number of Advantages Offered
Figure 8.1 Company Competitiveness Analysis: Benchmarking of Technology Strength
Figure 8.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Figure 8.3 Company Competitiveness Analysis: Developers based in North America
Figure 8.4 Company Competitiveness Analysis: Developers based in Europe and Asia
Figure 9.1 Adocia: Annual Revenues, 2015 – H1 2021 (EUR Million)
Figure 9.2 Ajinomoto: Annual Revenues, 2016 – H1 2021 (JPY Billion)
Figure 9.3 Ajinomoto Bio-Pharma Services: Crystalomics Technology
Figure 9.4 Alteogen: Annual Revenues, 2016 – H1 2021 (USD Million)
Figure 9.5 Arecor: Annual Revenues, 2018 – H1 2021 (EUR Million)
Figure 9.6 Arecor: Arestat Technology (Advantages)
Figure 9.7 Ascendis Pharma: Annual Revenues, 2015-H1 2021 (USD Million)
Figure 9.8 Avadel Pharmaceuticals: Annual Revenues, 2015 – 2020 (USD Million)
Figure 9.9 Avadel Pharmaceuticals: Medusa Technology
Figure 9.10 Camurus: Annual Revenues, 2015- H1 2021 (SEK)
Figure 9.11 Camurus: FluidCrystal Injection Depot Technology
Figure 9.12 DURECT: Annual Revenues, 2015-H1 2021 (USD Million)
Figure 9.13 DURECT: CLOUD Platform
Figure 9.14 Eagle Pharmaceuticals: Annual Revenues, 2015–H1 202 (USD Million)
Figure 9.15 Halozyme Therapeutics: Annual Revenues, 2015 – H1 2021 (USD Million)
Figure 9.16 MedinCell: Annual Revenues, 2015 – Q3 2021 (Euro Million)
Figure 9.17 MedinCell: BEPO Technology
Figure 9.18 Xeris Pharmaceuticals: Annual Revenues, 2016 – H1 2021 (USD Million)
Figure 9.19 Xeris Pharmaceuticals: XeriJect Technology
Figure 9.20 Xeris Pharmaceuticals: XeriSol Technology
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2021
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner and Partnership
Figure 10.8 Partnerships and Collaborations: Distribution Type of Partner and Company Size
Figure 10.9 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.10 Partnerships and Collaborations: Focus Area (Word Cloud)
Figure 10.11 Partnerships and Collaborations: Country-wise Distribution
Figure 10.12 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements Distribution
Figure 10.13 Most Active Players: Distribution by Number of Partnerships
Figure 11.1 Different Types of Subcutaneous Drug Delivery Systems
Figure 11.2 Large Volume Wearable Injectors: Overall Market Landscape
Figure 11.3 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Phase of Development
Figure 11.4 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Figure 11.5 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
Figure 11.6 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Technology Used
Figure 11.7 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Figure 11.8 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Method of Administration
Figure 11.9 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Figure 11.10 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Figure 11.11 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Figure 11.12 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Figure 11.13 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Figure 11.14 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity
Figure 11.15 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Compatibility
Figure 11.16 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Container
Figure 11.17 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 11.18 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Phase of Development
Figure 11.19 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Figure 11.20 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Figure 11.21 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Figure 11.22 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Figure 11.23 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
Figure 11.24 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non- Interoperable Device
Figure 11.25 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Figure 11.26 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Figure 11.27 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Features
Figure 11.28 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Figure 11.29 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
Figure 11.30 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Device Control Features
Figure 11.31 Most Active Players: Distribution by Number of Large Volume Wearable Injector for Insulin Drugs
Figure 11.32 Large Volume Drug Device Combinations: Distribution by Phase of Development
Figure 11.33 Large Volume Drug Device Combinations: Distribution by Type of Device
Figure 11.34 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Figure 11.35 Large Volume Drug Device Combinations: Distribution by Technology
Figure 11.36 Large Volume Drug Device Combinations: Distribution by Route of Administration
Figure 11.37 Large Volume Drug Device Combinations: Distribution by Method of Administration
Figure 11.38 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Figure 11.39 Large Volume Drug Device Combinations: Distribution by Type of Dose
Figure 11.40 Large Volume Drug Device Combinations: Distribution by Storage Volume / Capacity (in mL)
Figure 11.41 Large Volume Drug Device Combinations: Distribution by Usability
Figure 11.42 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Figure 11.43 Large Volume Drug Device Combinations: Distribution by Drug Container
Figure 11.44 Most Active Players: Distribution by Number of Products Manufactured
Figure 11.45 Autoinjectors: Distribution by Actuation Mechanism
Figure 11.46 Autoinjectors: Distribution by Route of Administration
Figure 11.47 Autoinjectors: Distribution by Type of Dose
Figure 11.48 Autoinjectors: Distribution by Storage Volume / Capacity (in ml)
Figure 11.49 Autoinjectors: Distribution by Usability
Figure 11.50 Autoinjectors: Distribution by Type of Primary Container
Figure 11.51 Autoinjectors: Distribution by Type of Feedback Mechanism
Figure 11.52 Most Active players: Distribution by Number of Devices
Figure 11.53 Pen Injectors: Distribution by Type of Dose
Figure 11.54 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
Figure 11.55 Pen Injectors: Distribution by Usability
Figure 11.56 Most Active Players: Distribution by Number of Devices
Figure 11.57 Needle Free Injection Systems: Distribution by Phase of Development
Figure 11.58 Needle Free Injection Systems: Distribution by Actuation Mechanism
Figure 11.59 Needle Free Injection Systems: Distribution by Therapeutic Area
Figure 11.60 Needle Free Injection Systems: Distribution by Usability
Figure 11.61 Most Active Players: Distribution by Number of Devices
Figure 11.62 Novel Drug Reconstitution Systems: Distribution by Volume Storage / Capacity (mL)
Figure 11.63 Novel Drug Reconstitution Systems: Distribution by Usability
Figure 11.64 Novel Drug Reconstitution Systems: Distribution by Type of Device
Figure 11.65 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Figure 11.66 Novel Drug Reconstitution Systems: Distribution by Type of Device and Chamber
Figure 11.67 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Figure 11.68 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Figure 11.69 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Usability
Figure 11.70 Most Active Players: Distribution by Number of Devices
Figure 11.71 Prefilled Syringes: Distribution by Storage Volume / Capacity (ml)
Figure 11.72 Prefilled Syringes: Distribution by Barrel Fabrication Material
Figure 11.73 Prefilled Syringes: Distribution by Number of Barrel Chambers
Figure 11.74 Prefilled Syringes: Distribution by Type of Needle System
Figure 11.75 Most Active Players: Distribution by Number of Devices
Figure 11.76 Implants: Distribution by Phase of Development
Figure 11.77 Implants: Distribution by Therapeutic Area
Figure 11.78 Implants: Distribution by Implant Material
Figure 11.79 Implants: Distribution by Treatment Duration
Figure 11.80 Implants: Distribution by Type of Delivery System
Figure 11.81 Most Active Players: Distribution By number of Devices
Figure 12.1 Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
Figure 12.2 Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
Figure 12.3 Product Competitiveness Analysis: Drug Device Combinations Products
Figure 12.4 Product Competitiveness Analysis: Disposable Autoinjectors
Figure 12.5 Product Competitiveness Analysis: Reusable Autoinjectors
Figure 12.6 Product Competitiveness Analysis: Spring-based Needle-Free Injection Systems
Figure 12.7 Product Competitiveness Analysis: Compressed Gas-powered Needle-Free Injection Systems
Figure 12.8 Product Competitiveness Analysis: Glass Barrel Prefilled Syringes
Figure 12.9 Product Competitiveness Analysis: Plastic Barrel Prefilled Syringes
Figure 13.1 Global Approved Subcutaneous Biologics Market, 2022-2035
Figure 13.2 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
Figure 13.3 Approved Subcutaneous Biologics Market for Antibodies, 2022-2035
Figure 13.4 Approved Subcutaneous Biologics Market for Nucleotides, 2022-2035
Figure 13.5 Approved Subcutaneous Biologics Market for Proteins, 2022-2035
Figure 13.6 Approved Subcutaneous Biologics Market for Vaccines, 2022-2035
Figure 13.7 Approved Subcutaneous Biologics Market for Other Biologics, 2022-2035
Figure 13.8 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
Figure 13.9 Approved Subcutaneous Biologics Market for Monotherapies, 2022-2035
Figure 13.10 Approved Subcutaneous Biologics Market for Combination Therapies, 2022-2035
Figure 13.11 Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, 2022-2035
Figure 13.12 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
Figure 13.13 Approved Subcutaneous Biologics Market for Autoimmune Disorders, 2022-2035
Figure 13.14 Approved Subcutaneous Biologics Market for Blood Disorders, 2022-2035
Figure 13.15 Approved Subcutaneous Biologics Market for Bone Disorders, 2022-2035
Figure 13.16 Approved Subcutaneous Biologics Market for Cardiovascular Disorders, 2022-2035
Figure 13.17 Approved Subcutaneous Biologics Market for Genetic Disorders, 2022-2035
Figure 13.18 Approved Subcutaneous Biologics Market for Hormonal Disorders, 2022-2035
Figure 13.19 Approved Subcutaneous Biologics Market for Infectious Disorders, 2022-2035
Figure 13.20 Approved Subcutaneous Biologics Market for Inflammatory Disorders, 2022-2035
Figure 13.21 Approved Subcutaneous Biologics Market for Metabolic Disorders, 2022-2035
Figure 13.22 Approved Subcutaneous Biologics Market for Neurological Disorders, 2022-2035
Figure 13.23 Approved Subcutaneous Biologics Market for Oncological Disorders, 2022-2035
Figure 13.24 Approved Subcutaneous Biologics Market for Respiratory Disorders, 2022-2035
Figure 13.25 Approved Subcutaneous Biologics Market for Women’s Health Disorders, 2022-2035
Figure 13.26 Approved Subcutaneous Biologics Market for Other Disorders, 2022-2035
Figure 13.27 Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
Figure 13.28 Approved Subcutaneous Biologics Market in North America, 2022-2035
Figure 13.29 Approved Subcutaneous Biologics Market in Europe, 2022-2035
Figure 13.30 Approved Subcutaneous Biologics Market in Asia, 2022-2035
Figure 13.31 Approved Subcutaneous Biologics Market in Middle East and North Africa, 2022-2035
Figure 13.32 Approved Subcutaneous Biologics Market in Latin America, 2022-2035
Figure 13.33 Approved Subcutaneous Biologics Market in Rest of the World, 2022-2035
Figure 13.34 AIMOVIG Sales Forecast, 2022-2035 (USD Million)
Figure 13.35 AJOVY Sales Forecast, 2022-2035 (USD Million)
Figure 13.36 Apidra (insulin glulisine), Sales Forecast, 2022-2035 (USD Million)
Figure 13.37 Basaglar / Abrasia (EU) Sales Forecast, 2022-2035 (USD Million)
Figure 13.38 BENLYSTA(belimumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.39 BESREMi (ropeginterferon alfa-2b-njft) Sales Forecast, 2022-2035 (USD Million)
Figure 13.40 BIOTHRAX® (Anthrax Vaccine Adsorbed) Sales Forecast, 2022-2035 (USD Million)
Figure 13.41 CABLIVI (Caplacizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.42 Cegfila Sales Forecast, 2022-2035 (USD Million)
Figure 13.43 CIMZIA (certolizumab pegol) Sales Forecast, 2022-2035 (USD Million)
Figure 13.44 COSENTYX (secukinumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.45 CRYSVITA (burosumab-twza) Sales Forecast, 2022-2035 (USD Million)
Figure 13.46 Cuvitru (immune globulin subcutaneous [human], 20% solution) Sales Forecast, 2022-2035 (USD Million)
Figure 13.47 DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj / DARZALEX SC Sales Forecast, 2022-2035 (USD Million)
Figure 13.48 DENGVAXIA (Dengue Tetravalent Vaccine) Sales Forecast, 2022-2035 (USD Million)
Figure 13.49 DUPIXENT (dupilumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.50 EMGALITY (galcanezumab-gnlm) Sales Forecast, 2022-2035 (USD Million)
Figure 13.51 EMPAVELI (pegcetacoplan) Sales Forecast, 2022-2035 (USD Million)
Figure 13.52 Enbrel (etanercept) Sales Forecast, 2022-2035 (USD Million)
Figure 13.53 ENSPRYNG (satralizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.54 EVENITY (romosozumab-aqqg) Sales Forecast, 2022-2035 (USD Million)
Figure 13.55 FASENRA (benralizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.56 FIASP (Insulin Aspart) Sales Forecast, 2022-2035 (USD Million)
Figure 13.57 Fulphila (pegfilgrastim-jmdb) Sales Forecast, 2022-2035 (USD Million)
Figure 13.58 Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate/Chromatography Purified) Sales Forecast, 2022-2035 (USD Million)
Figure 13.59 GATTEX / Revestive (teduglutide [rDNA origin]) Sales Forecast, 2022-2035 (USD Million)
Figure 13.60 GIVLAARI (givosiran) Sales Forecast, 2022-2035 (USD Million)
Figure 13.61 HAEGARDA Sales Forecast, 2022-2035 (USD Million)
Figure 13.62 HEMLIBRA (emicizumab-kxwh) Sales Forecast, 2022-2035 (USD Million)
Figure 13.63 Hepcludex (Bulevirtide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.64 Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) Sales Forecast, 2022-2035 (USD Million)
Figure 13.65 HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) Sales Forecast, 2022-2035 (USD Million)
Figure 13.66 ILARIS (canakinumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.67 ILUMYA (tildrakizumab-asmn) / Ilumetri Sales Forecast, 2022-2035 (USD Million)
Figure 13.68 Kalbitor (ecallantide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.69 Kesimpta (ofatumumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.70 KEVZARA (sarilumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.71 KINERET (anakinra) Sales Forecast, 2022-2035 (USD Million)
Figure 13.72 Kyntheum / SILIQ / Lumicef (brodalumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.73 Leqvio (Inclisiran) Sales Forecast, 2022-2035 (USD Million)
Figure 13.74 Lonquex (lipegfilgrastim) Sales Forecast, 2022-2035 (USD Million)
Figure 13.75 Lyumjev (insulin lispro-aabc) Sales Forecast, 2022-2035 (USD Million)
Figure 13.76 Norditropin (somatropin) Sales Forecast, 2022-2035 (USD Million)
Figure 13.77 NPLATE (romiplostim) Sales Forecast, 2022-2035 (USD Million)
Figure 13.78 Nucala (mepolizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.79 OXLUMO (lumasiran) Sales Forecast, 2022-2035 (USD Million)
Figure 13.80 PALYNZIQ (pegvaliase-pqpz) Sales Forecast, 2022-2035 (USD Million)
Figure 13.81 Pergoveris (follitropin alfa / lutropin alfa) Sales Forecast, 2022-2035 (USD Million)
Figure 13.82 Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Sales Forecast, 2022-2035 (USD Million)
Figure 13.83 Prolia / Pralia (denosumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.84 REBLOZYL (luspatercept-aamt) Sales Forecast, 2022-2035 (USD Million)
Figure 13.85 REKOVELLE (follitropin delta) Sales Forecast, 2022-2035 (USD Million)
Figure 13.86 Repatha (evolocumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.87 RYZODEG 70/30 (insulin degludec and insulin aspart) Sales Forecast, 2022-2035 (USD Million)
Figure 13.88 Skyrizi (risankizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.89 SKYTROFA (lonapegsomatropin-tcgd) Sales Forecast, 2022-2035 (USD Million)
Figure 13.90 SOLIQUA 100/33 (insulin glargine & lixisenatide injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.91 STELARA (ustekinumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.92 Strensiq (asfotase alfa) Sales Forecast, 2022-2035 (USD Million)
Figure 13.93 TAKHZYRO (lanadelumab-flyo) Sales Forecast, 2022-2035 (USD Million)
Figure 13.94 Taltz (ixekizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.95 TEGSEDI (inotersen) Sales Forecast, 2022-2035 (USD Million)
Figure 13.96 Toujeo (insulin glargine injection) U-300 Sales Forecast, 2022-2035 (USD Million)
Figure 13.97 TREMFYA (guselkumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.98 TRESIBA (insulin degludec injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.99 Trulicity (dulaglutide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.100 TYMLOS (abaloparatide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.101 Tysabri (Natalizumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.102 Voxzogo (vosoritide) Sales Forecast, 2022-2035 (USD Million)
Figure 13.103 VYLEESI (bremelanotide injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.104 XEMBIFY (immune globulin subcutaneous, human – klhw) Sales Forecast, 2022-2035 (USD Million)
Figure 13.105 Xgeva / RANMARK (denosumab) Sales Forecast, 2022-2035 (USD Million)
Figure 13.106 XULTOPHY / IDegLira (insulin degludec and liraglutide injection) Sales Forecast, 2022-2035 (USD Million)
Figure 13.107 XYOSTED (testosterone enanthate) Sales Forecast, 2022-2035 (USD Million)
Figure 13.108 ZEGALOGUE (dasiglucagon) Sales Forecast, 2022-2035 (USD Million)
Figure 14.1 Global Subcutaneous Formulation Technologies Market, 2022-2035
Figure 14.2 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022 and 2035
Figure 14.3 Subcutaneous Formulation Technologies Market for Milestone Payments, 2022-2035
Figure 14.4 Subcutaneous Formulation Technologies Market for Upfront Payments, 2022-2035
Figure 14.5 Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022 and 2035
Figure 14.6 Subcutaneous Formulation Technologies Market for Amino Acid Interaction, 2022-2035
Figure 14.7 Subcutaneous Formulation Technologies Market for Complex Formation, 2022-2035
Figure 14.8 Subcutaneous Formulation Technologies Market for Encapsulation, 2022-2035
Figure 14.9 Subcutaneous Formulation Technologies Market for Other Fundamental Principles, 2022-2035
Figure 14.10 Subcutaneous Formulation Technologies Market: Distribution by End Users, 2022 and 2035
Figure 14.11 Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, 2022-2035
Figure 14.12 Subcutaneous Formulation Technologies Market for Biotechnology Companies, 2022-2035
Figure 14.13 Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, 2022-2035
Figure 14.14 Subcutaneous Formulation Technologies Market for Educational Institutes, 2022-2035
Figure 14.15 Subcutaneous Formulation Technologies Market for Investors, 2022-2035
Figure 14.16 Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, 2022-2035
Figure 14.17 Subcutaneous Formulation Technologies Market for Research Institutes, 2022-2035
Figure 14.18 Subcutaneous Formulation Technologies Market for Other End Users, 2022-2035
Figure 14.19 Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
Figure 14.20 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, 2022-2035
Figure 14.21 Subcutaneous Formulation Technologies Market for Genetic Disorders, 2022-2035
Figure 14.22 Subcutaneous Formulation Technologies Market for Infectious Disorders, 2022-2035
Figure 14.23 Subcutaneous Formulation Technologies Market for Metabolic Disorders, 2022-2035
Figure 14.24 Subcutaneous Formulation Technologies Market for Oncological Disorders, 2022-2035
Figure 14.25 Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, 2022-2035
Figure 14.26 Subcutaneous Formulation Technologies Market for Other Disorders, 2022-2035
Figure 14.27 Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
Figure 14.28 Subcutaneous Formulation Technologies Market in North America, 2022-2035
Figure 14.29 Subcutaneous Formulation Technologies Market in Europe, 2022-2035
Figure 14.30 Subcutaneous Formulation Technologies Market in Asia, 2022-2035
Figure 15.1 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (USD Million)
Figure 15.2 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.3 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.4 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.5 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (USD Million)
Figure 15.6 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.7 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.8 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.9 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021- 2035 (USD Million)
Figure 15.10 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.11 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.12 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.13 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (USD Million)
Figure 15.14 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.15 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.16 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.17 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (USD Million)
Figure 15.18 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.19 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.20 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.21 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (USD Million)
Figure 15.22 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.23 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.24 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (USD Million)
Figure 15.25 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, 2021-2035 (Million Units)
Figure 15.26 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.27 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.28 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.29 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, 2021-2035 (Million Units)
Figure 15.30 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.31 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.32 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.33 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, 2021- 2035 (Million Units)
Figure 15.34 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.35 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.36 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.37 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, 2021-2035 (Million Units)
Figure 15.38 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.39 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.40 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.41 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, 2021-2035 (Million Units)
Figure 15.42 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.43 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.44 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.45 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, 2021-2035 (Million Units)
Figure 15.46 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (Million Units)
Figure 15.47 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, 2021-2035 (Million Units)
Figure 15.48 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, 2021-2035 (Million Units)
Figure 15.49 Global Large Volume Wearable Injectors Market for Insulin, 2021-2035 (USD Billion)
Figure 15.50 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.51 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.52 Large Volume Wearable Injectors Market for Insulin in North America, 2021-2035 (USD Million)
Figure 15.53 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.54 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.55 Large Volume Wearable Injectors Market for Insulin in Europe, 2021-2035 (USD Million)
Figure 15.56 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.57 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.58 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, 2021-2035 (USD Million)
Figure 15.59 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.60 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.61 Large Volume Wearable Injectors Market for Insulin in Latin America, 2021-2035 (USD Million)
Figure 15.62 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.63 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.64 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, 2021-2035 (USD Million)
Figure 15.65 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, 2021-2035 (USD Million)
Figure 15.66 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, 2021-2035 (USD Million)
Figure 15.67 Global Autoinjectors Market, 2021-2035 (USD Billion)
Figure 15.68 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.69 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.70 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.71 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.72 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (USD Billion)
Figure 15.73 Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (USD Billion)
Figure 15.74 Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (USD Billion)
Figure 15.75 Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.76 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (USD Billion)
Figure 15.77 Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.78 Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.79 Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.80 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.81 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.82 Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.83 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.84 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.85 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (USD Billion)
Figure 15.86 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (USD Billion)
Figure 15.87 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.88 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (USD Billion)
Figure 15.89 Global Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.90 Global Disposable Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.91 Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.92 Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.93 Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (USD Billion)
Figure 15.94 Autoinjectors Market for Migraine in North America, 2021-2035 (USD Billion)
Figure 15.95 Autoinjectors Market for Migraine in Europe, 2021-2035 (USD Billion)
Figure 15.96 Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.97 Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (USD Billion)
Figure 15.98 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.99 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.100 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.101 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.102 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.103 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.104 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.105 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (USD Billion)
Figure 15.106 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (USD Billion)
Figure 15.107 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (USD Billion)
Figure 15.108 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.109 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (USD Billion)
Figure 15.110 Global Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.111 Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.112 Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.113 Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.114 Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (USD Billion)
Figure 15.115 Autoinjectors Market for Diabetes in North America, 2021-2035 (USD Billion)
Figure 15.116 Autoinjectors Market for Diabetes in Europe, 2021-2035 (USD Billion)
Figure 15.117 Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.118 Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (USD Billion)
Figure 15.119 Global Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.120 Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.121 Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.122 Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.123 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.124 Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.125 Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.126 Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.127 Autoinjectors Market for Other Indications in North America, 2021-2035 (USD Billion)
Figure 15.128 Autoinjectors Market for Other Indications in Europe, 2021-2035 (USD Billion)
Figure 15.129 Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.130 Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (USD Billion)
Figure 15.131 Global Autoinjectors Market, 2021-2035 (Million Units)
Figure 15.132 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.133 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.134 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.135 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.136 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Figure 15.137 Autoinjectors Market for Anaphylaxis in North America, 2021-2035 (Million Units)
Figure 15.138 Autoinjectors Market for Anaphylaxis in Europe, 2021-2035 (Million Units)
Figure 15.139 Autoinjectors Market for Anaphylaxis in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.140 Autoinjectors Market for Anaphylaxis in Rest of the World, 2021-2035 (Million Units)
Figure 15.141 Global Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.142 Global Disposable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.143 Global Reusable Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.144 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, 2021-2035 (USD Billion)
Figure 15.145 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.146 Global Protein-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.147 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.148 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, 2021-2035 (Million Units)
Figure 15.149 Autoinjectors Market for Multiple Sclerosis in North America, 2021-2035 (Million Units)
Figure 15.150 Autoinjectors Market for Multiple Sclerosis in Europe, 2021-2035 (Million Units)
Figure 15.151 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.152 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (Million Units)
Figure 15.153 Global Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.154 Global Disposable Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.155 Global Subcutaneous Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.156 Global Antibody-based Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.157 Global Small Molecule-based Autoinjectors Market for Migraine, 2021-2035 (Million Units)
Figure 15.158 Autoinjectors Market for Migraine in North America, 2021-2035 (Million Units)
Figure 15.159 Autoinjectors Market for Migraine in Europe, 2021-2035 (Million Units)
Figure 15.160 Autoinjectors Market for Migraine in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.161 Autoinjectors Market for Migraine in Rest of the World, 2021-2035 (Million Units)
Figure 15.162 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.163 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.164 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.165 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.166 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.167 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.168 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.169 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, 2021-2035 (Million Units)
Figure 15.170 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, 2021-2035 (Million Units)
Figure 15.171 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, 2021-2035 (Million Units)
Figure 15.172 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, 2021-2035 (USD Billion)
Figure 15.173 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, 2021-2035 (Million Units)
Figure 15.174 Global Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.175 Global Disposable Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.176 Global Subcutaneous Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.177 Global Protein-based Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.178 Global Peptide-based Autoinjectors Market for Diabetes, 2021-2035 (Million Units)
Figure 15.179 Autoinjectors Market for Diabetes in North America, 2021-2035 (Million Units)
Figure 15.180 Autoinjectors Market for Diabetes in Europe, 2021-2035 (Million Units)
Figure 15.181 Autoinjectors Market for Diabetes in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.182 Autoinjectors Market for Diabetes in Rest of the World, 2021-2035 (Million Units)
Figure 15.183 Global Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.184 Global Disposable Autoinjectors Market for Other Indications, 2021-2035 (USD Billion)
Figure 15.185 Global Subcutaneous Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.186 Global Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.187 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.188 Global Protein-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.189 Global Antibody-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.190 Global Small Molecule-based Autoinjectors Market for Other Indications, 2021-2035 (Million Units)
Figure 15.191 Autoinjectors Market for Other Indications in North America, 2021-2035 (Million Units)
Figure 15.192 Autoinjectors Market for Other Indications in Europe, 2021-2035 (Million Units)
Figure 15.193 Autoinjectors Market for Other Indications in Asia-Pacific, 2021-2035 (Million Units)
Figure 15.194 Autoinjectors Market for Other Indications in Rest of the World, 2021-2035 (Million Units)
Figure 15.195 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Figure 15.196 Global Prefilled Syringes Market, 2020-2030 (USD Million)
Figure 15.197 Global Prefilled Syringes Market, 2020-2030 (Million, Units)
Figure 15.198 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
Figure 15.199 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
Figure 15.200 Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020, 2025 and 2030 (USD Million)
Figure 15.201 Prefilled Syringes Market: Distribution by Target Therapeutic Area, 2020-2030
Figure 15.202 Global Needle-free Injection Systems Market, 2020-2030 (USD Million)
Figure 15.203 Global Needle-free Injection Systems Market: Distribution by Product Usability, 2020-2030, (USD Million)
Figure 15.204 Global Needle-free Injection Systems Market: Distribution by Actuation Mechanism, 2020-2030 (USD Million)
Figure 15.205 Global Needle-free Injection Systems Market: Distribution by Target Therapeutic Area, 2020-2030 (USD Million)
Figure 15.206 Global Novel Drug Reconstitution Systems Market, 2021-2030 (USD Billion)
Figure 15.207 Global Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 15.208 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Physical State of Drug
Figure 15.209 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
Figure 15.210 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
Figure 15.211 Dual Chamber Prefilled Syringes Market, 2021 and2030: Distribution by Type of Fabrication Material Used
Figure 15.212 Glass Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 15.213 Plastic Dual Chamber Prefilled Syringes Market, 2021-2030 (USD Billion)
Figure 15.214 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
Figure 15.215 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, 2021-2030 (USD Billion)
Figure 15.216 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, 2021-2030 (USD Billion)
Figure 15.217 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, 2021-2030 (USD Billion)
Figure 15.218 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, 2021-2030 (USD Billion)
Figure 15.219 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Geography
Figure 15.220 Dual Chamber Prefilled Syringes Market in North America, 2021-2030 (USD Billion)
Figure 15.221 Dual Chamber Prefilled Syringes Market in Europe, 2021-2030 (USD Billion)
Figure 15.222 Dual Chamber Prefilled Syringes Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 15.223 Dual Chamber Prefilled Syringes Market in Latin America, 2021-2030 (USD Billion)
Figure 15.224 Dual Chamber Prefilled Syringes Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 15.225 Global Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 15.226 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Physical State of Drug
Figure 15.227 Dual Chamber Cartridges Market for Liquid / Powder Drugs, 2021-2030 (USD Billion)
Figure 15.228 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, 2021-2030 (USD Billion)
Figure 15.229 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Type of Fabrication Material Used
Figure 15.230 Glass Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 15.231 Plastic Dual Chamber Cartridges Market, 2021-2030 (USD Billion)
Figure 15.232 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Volume
Figure 15.233 Dual Chamber Cartridges Market for <1 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.234 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.235 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.236 Dual Chamber Cartridges Market for >5 mL Cartridges, 2021-2030 (USD Billion)
Figure 15.237 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
Figure 15.238 Dual Chamber Cartridges Market in North America, 2021-2030 (USD Billion)
Figure 15.239 Dual Chamber Cartridges Market in Europe, 2021-2030 (USD Billion)
Figure 15.240 Dual Chamber Cartridges Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 15.241 Dual Chamber Cartridges Market in Latin America, 2021-2030 (USD Billion)
Figure 15.242 Dual Chamber Cartridges Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 15.243 Global Dual / Multi Chamber Infusion Bags Market, 2021-2030 (USD Billion)
Figure 15.244 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
Figure 15.245 Dual / Multi Chamber Infusion Bags Market for Liquid Drugs, 2021-2030 (USD Billion)
Figure 15.246 Dual / Multi Chamber Infusion Bags Market for Frozen Drugs, 2021-2030 (USD Billion)
Figure 15.247 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic Bags
Figure 15.248 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate Bags, 2021-2030 (USD Billion)
Figure 15.249 Dual / Multi Chamber Infusion Bags Market for Polypropylene Bags, 2021-2030 (USD Billion)
Figure 15.250 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride Bags, 2021-2030 (USD Billion)
Figure 15.251 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials Bags, 2021-2030 (USD Billion)
Figure 15.252 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
Figure 15.253 Dual / Multi Chamber Infusion Bags Market for <250 mL Bags, 2021-2030 (USD Billion)
Figure 15.254 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Bags, 2021- 2030 (USD Billion)
Figure 15.255 Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Bags, 2021-2030 (USD Billion)
Figure 15.256 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Bags, 2021- 2030 (USD Billion)
Figure 15.257 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
Figure 15.258 Dual / Multi Chamber Infusion Bags Market in North America, 2021-2030 (USD Billion)
Figure 15.259 Dual / Multi Chamber Infusion Bags Market in Europe, 2021-2030 (USD Billion)
Figure 15.260 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, 2021-2030 (USD Billion)
Figure 15.261 Dual / Multi Chamber Infusion Bags Market in Latin America, 2021-2030 (USD Billion)
Figure 15.266 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, 2021-2030 (USD Billion)
Figure 16.1 Subcutaneous Biologics SWOT Analysis: Overview
Figure 16.2 SWOT Analysis: Harvey Ball Analysis
Figure 16.3 Number of Biologics Approved by the USFDA, 2011-2020
Figure 17.1 Concluding Remarks: Approve Subcutaneous Biologics Market Landscape
Figure 17.2 Concluding Remarks: Clinical-Stage Subcutaneous Biologics Market Landscape
Figure 17.3 Concluding Remarks: Success Protocol Analysis
Figure 17.4 Concluding Remarks: Formulation Technology Market Landscape
Figure 17.5 Concluding Remarks: Company Competitiveness Analysis: Providers based in North America
Figure 17.6 Concluding Remarks: Partnerships and Collaborations
Figure 17.7 Concluding Remarks: Subcutaneous Drug Delivery Systems Market Landscape
Figure 17.8 Concluding Remarks: Product Competitiveness Analysis: Subcutaneous Drug Delivery Systems
Figure 17.9 Concluding Remarks: Product Competitiveness Analysis: Subcutaneous Drug Delivery Systems
Figure 17.10 Concluding Remarks: Approved Subcutaneous Biologics Market Forecast
Figure 17.11 Concluding Remarks: Approved Subcutaneous Biologics Market Forecast

List Of Tables

Table 3.1 Comparison of Characteristics of Small Molecules and Biologics
Table 3.2 Parenteral Routes of Administration
Table 3.3 Parenteral Drug Formulations: Associated Physical and Chemical Instabilities
Table 3.4 Parenteral Drug Formulations: Key Excipients
Table 4.1 List of Approved Subcutaneous Biologics
Table 4.2 Approved Subcutaneous Biologics: Information on Targeted Indication and Therapeutic Area
Table 4.3 Approved Subcutaneous Biologics: Information on Dosing Frequency, Dose Concentration and Therapeutic Area
Table 4.4 Approved Subcutaneous Biologics: Information on Available Formulation
Table 4.5 Subcutaneous Biologics: List of Companies
Table 5.1 List of Clinical Subcutaneous Biologics
Table 5.2 Clinical Subcutaneous Biologics: Information on Type of Therapy, Dosing Frequency, Therapeutic Area, Special Drug Designation(s) Awarded
Table 5.3 Clinical Subcutaneous Biologics: List of Companies
Table 6.1 BENLYSTA (Human Genome Sciences): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.2 BESREMi (PharmaEssentia): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.3 COSENTYX (Novartis)Trulicity® (Eli Lilly): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.4 DARZALEX FASPRO (Halozyme): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.5 DUPIXENT (Regeneron Pharmaceuticals): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.6 Enbrel (Amgen): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.7 HEMLIBRA (Roche): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.8 Prolia / Pralia (Amgen): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.9 STELARA (Janssen Biotech): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 6.10 Trulicity (Eli Lilly): Information on Target Disease Indication(s), Route of Administration, and Phase of Development
Table 7.1 Subcutaneous Formulation Technologies: List of Technology Developers
Table 7.2 Subcutaneous Formulation Technologies: Information on Fundamental Principle and Type of Molecule
Table 7.3 Subcutaneous Formulation Technologies: Information on Route of Administration
Table 7.4 Subcutaneous Formulation Technologies: Information on Therapeutics Area and Key Characteristics
Table 8.1 Company Competitiveness Analysis: Benchmarking of Technology Strength
Table 8.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 8.3 Company Competitiveness Analysis: Players Based in North America
Table 8.4 Company Competitiveness Analysis: Players Based in Europe and Asia
Table 9.1 Subcutaneous Formulation Technologies Developers: List of Companies Profiled
Table 9.2 Adocia: Company Overview
Table 9.3 Adocia: Product Portfolio
Table 9.4 Adocia: Recent Developments and Future Outlook
Table 9.5 Ajinomoto: Company Overview
Table 9.6 Ajinomoto Biopharma: Recent Developments and Future Outlook
Table 9.7 Alteogen: Company Overview
Table 9.8 Alteogen: Product Portfolio
Table 9.9 Alteogen: Recent Developments and Future Outlook
Table 9.10 Arecor: Company Overview
Table 9.11 Arecor: Product Portfolio
Table 9.12 Arecor: Recent Developments and Future Outlook.
Table 9.13 Ascendis Pharma: Company Overview
Table 9.14 Ascendis Pharma: Product Portfolio
Table 9.15 Ascendis Pharma: Recent Developments and Future Outlook.
Table 9.16 Avadel Pharmaceutical: Company Overview
Table 9.17 Avadel Pharmaceuticals: Product Portfolio
Table 9.18 Avadel Pharmaceuticals: Recent Developments and Future Outlook.
Table 9.19 Camurus: Company Overview
Table 9.20 Camurus: Product Portfolio
Table 9.21 Camurus: Recent Developments and Future Outlook
Table 9.22 Creative Biolabs: Company Overview
Table 9.23 Creative Biomart: Company Overview
Table 9.24 DURECT: Company Overview
Table 9.25 DURECT: Product Portfolio
Table 9.26 DURECT: Recent Developments and Future Outlook
Table 9.27 Eagle Pharmaceutical: Company Overview
Table 9.28 Eagle Pharmaceutical: Recent Developments and Future Outlook
Table 9.29 Halozyme Therapeutics: Company Overview
Table 9.30 Halozyme Therapeutics: Product Portfolio
Table 9.31 Halozyme Therapeutics: Recent Developments and Future Outlook
Table 9.32 Medincell: Company Overview
Table 9.33 MedinCell: Product Portfolio
Table 9.34 MedinCell: Recent Developments and Future Outlook.
Table 9.35 Serina Therapeutics: Company Overview
Table 9.36 Serina Therapeutics: Product Portfolio
Table 9.37 Serina Therapeutics: Recent Developments and Future Outlook
Table 9.38 Xeris pharmaceutical: Company Overview
Table 9.39 Xeris Pharmaceuticals: Product Portfolio
Table 9.40 Xeris Pharmaceuticals: Recent Developments and Future Outlook
Table 10.1 Subcutaneous Formulation Technologies: List of Partnerships, Pre-2016-2021
Table 10.2 Subcutaneous Formulation Technologies: Information on Type of Agreement Region-wise and Geography-wise)
Table 11.1 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Development Status and Device Features
Table 11.2 Large Volume Wearable Injectors for Non-Insulin Drugs: Information on Administration Related Parameters
Table 11.3 Large Volume Wearable Injectors for Insulin Drugs: Information on Development Status and Device Features
Table 11.4 Large Volume Wearable Injectors for Insulin Drugs: Information on Device Monitoring and Connectivity Features
Table 11.5 Large Volume Drug Device Combinations: Information on Development Status and Device Features
Table 11.6 Large Volume Drug Device Combinations: Information on Drug Administration Related Parameters
Table 11.7 Autoinjectors: Development Pipeline
Table 11.8 Autoinjectors: List of Additional Parameters of Devices
Table 11.9 Pen Injectors: Development Landscape
Table 11.10 List of Smart Pen Injectors
Table 11.11 List of Drug and Pen Injector Combination Products
Table 11.12 Needle Free Injection Systems: Development Landscape
Table 11.13 Novel Drug Reconstitution Systems: Information on Type of Product, Number of Chambers, Physical State of Drug and Product Certifications
Table 11.14 Novel Drug Reconstitution Systems: Information on Container Fabrication Material, Volume, Drug Class, Device Usability and Provisions for Self-Administration
Table 11.15 Prefilled Syringes: List of Available / Under Development Devices
Table 11.16 Drugs Approved in Prefilled Syringes, 2013-2019
Table 11.17 Other Drugs Sold in Prefilled Syringes
Table 11.18 Implants: Development Landscape
Table 11.19 Implants: Information on Material Type, Treatment Duration and Type of Delivery System
Table 11.20 Implants: Subcutaneous Implants Eluting Small Molecules
Table 19.1 Approved Subcutaneous Biologics: Distribution by Approval Year
Table 19.2 Approved Subcutaneous Biologics: Distribution by Type of Molecule
Table 19.3 Approved Subcutaneous Biologics: Distribution by Approval Year and Type of Molecule
Table 19.4 Approved Subcutaneous Biologics: Distribution by Type of Therapy
Table 19.5 Approved Subcutaneous Biologics: Distribution by Route of Administration
Table 19.6 Approved Subcutaneous Biologics: Distribution by Method of Administration
Table 19.7 Approved Subcutaneous Biologics: Distribution by Route of Administration and Method of Administration
Table 19.8 Approved Subcutaneous Biologics: Distribution by Dosing Frequency
Table 19.9 Approved Subcutaneous Biologics: Distribution by Dose Concentration
Table 19.10 Approved Subcutaneous Biologics: Distribution by Therapeutic Area
Table 19.11 Approved Subcutaneous Biologics: Distribution by Approval Year and Therapeutic Area
Table 19.12 Approved Subcutaneous Biologics: Distribution by Type of Available Formulation
Table 19.13 Approved Subcutaneous Biologics: Distribution by Route of Administration and Type of Available Formulations
Table 19.14 Approved Subcutaneous Biologics Developers: Distribution by Year of Establishment
Table 19.15 Approved Subcutaneous Biologics Developers: Distribution by Company Size
Table 19.16 Approved Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Table 19.17 Leading Developers: Distribution by Number of Approved Subcutaneous Biologics
Table 19.18 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development
Table 19.19 Clinical-Stage Subcutaneous Biologics: Distribution by Mechanism of Action
Table 19.20 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule
Table 19.21 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Type of Molecule
Table 19.22 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Therapy
Table 19.23 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Type of Therapy
Table 19.24 Clinical-Stage Subcutaneous Biologics: Distribution by Dosing Frequency
Table 19.25 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Dosing Frequency
Table 19.26 Clinical-Stage Subcutaneous Biologics: Distribution by Target Disease Indication(s)
Table 19.27 Clinical-Stage Subcutaneous Biologics: Distribution by Therapeutics Area
Table 19.28 Clinical-Stage Subcutaneous Biologics: Distribution by Phase of Development and Therapeutics Area
Table 19.29 Clinical-Stage Subcutaneous Biologics: Distribution by Type of Molecule and Therapeutics Area
Table 19.30 Clinical-Stage Subcutaneous Biologics: Distribution by Special Drug Designation(s) Awarded
Table 19.31 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Year of Establishment
Table 19.32 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Company Size
Table 19.33 Clinical-Stage Subcutaneous Biologics Developers: Distribution by Location of Headquarters
Table 19.34 Leading Developers: Distribution by Number of Clinical-Stage Subcutaneous Biologics
Table 19.35 Subcutaneous Formulation Technology: Distribution by Fundamental Principle of Technology
Table 19.36 Subcutaneous Formulation Technology: Distribution by Type of Molecule
Table 19.37 Subcutaneous Formulation Technologies: Distribution by Route of Administration
Table 19.38 Subcutaneous Formulation Technologies: Distribution by Type of Molecule and Route of Administration
Table 19.39 Subcutaneous Formulation Technologies: Distribution by Therapeutic Area
Table 19.40 Subcutaneous Formulation Technologies: Distribution by Advantage(s) Offered
Table 19.41 Subcutaneous Formulation Technology Developers: Distribution by Year of Establishment
Table 19.42 Subcutaneous Formulation Technology Developers: Distribution by Company Size
Table 19.43 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Region Wise)
Table 19.44 Subcutaneous Formulation Technology Developers: Distribution by Location of Headquarters (Country-Wise)
Table 19.45 Subcutaneous Formulation Technology Developers: Distribution by Company Size and Location of Headquarters (Region Wise)
Table 19.46 Subcutaneous Formulation Technologies: Distribution by Number of Advantages Offered
Table 19.47 Adocia: Annual Revenues, 2015 – H1 2021 (EUR Million)
Table 19.48 Ajinomoto: Annual Revenues, 2016 – H1 2021 (JPY Billion)
Table 19.49 Alteogen : Annual Revenues, 2018 – H1 2021 (USD Million)
Table 19.50 Arecor: Annual Revenues, 2016 – H1 2021 (USD Million)
Table 19.52 Ascendis Pharma: Annual Revenues, 2015-H1 2021 (USD Million)
Table 19.53 Avadel Pharmaceuticals: Annual Revenues, 2015 – 2020 (USD Million)
Table 19.54 Camurus: Annual Revenues, 2015- H1 2021 (SEK)
Table 19.55 DURECT: Annual Revenues, 2015-H1 2021 (USD Million)
Table 19.56 Eagle Pharmaceuticals: Annual Revenues, 2015–H1 202 (USD Million)
Table 19.57 Halozyme Therapeutics: Annual Revenues, 2015 – H1 2021 (USD Million)
Table 19.58 MedinCell: Annual Revenues, 2015 – Q3 2021 (Euro Million)
Table 19.59 Xeris Pharmaceuticals: Annual Revenues, 2016 – H1 2021 (USD Million)
Table 19.60 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2016-2021
Table 19.61 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.62 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 19.63 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 19.64 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.65 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 19.66 Partnerships and Collaborations: Distribution by Type of Partner and Partnership
Table 19.67 Partnerships and Collaborations: Distribution Type of Partner and Company Size
Table 19.68 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 19.69 Partnerships and Collaborations: Country-wise Distribution
Table 19.70 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements Distribution
Table 19.71 Most Active Players: Distribution by Number of Partnerships
Table 19.72 Large Volume Wearable Injectors: Overall Market Landscape
Table 19.73 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Phase of Development
Table 19.74 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Device
Table 19.75 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Actuation Mechanism
Table 19.76 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Technology Used
Table 19.77 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Route of Administration
Table 19.78 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Method of Administration
Table 19.79 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Therapeutic Area
Table 19.80 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Type of Dose
Table 19.81 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Table 19.82 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Usability
Table 19.83 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Table 19.84 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Connectivity
Table 19.85 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Compatibility
Table 19.86 Large Volume Wearable Injectors for Non-Insulin Drugs: Distribution by Availability of Drug Container
Table 19.87 Most Active Players: Distribution by Number of Large Volume Wearable Injectors for Non-Insulin Drugs
Table 19.88 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Phase of Development
Table 19.89 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Device
Table 19.90 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Dose
Table 19.91 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Storage Volume / Capacity (in mL)
Table 19.92 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Usability
Table 19.93 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Combination Insulin
Table 19.94 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Non- Interoperable Device
Table 19.95 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Prefilled Drug Reservoir
Table 19.96 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
Table 19.97 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Type of Automated Insulin Delivery (AID) Feature
Table 19.98 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
Table 19.99 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Connectivity
Table 19.100 Large Volume Wearable Injectors for Insulin Drugs: Distribution by Availability of Device Control Features
Table 19.101 Most Active Players: Distribution by Number of Large Volume Wearable Injector for Insulin Drugs
Table 19.102 Large Volume Drug Device Combinations: Distribution by Phase of Development
Table 19.103 Large Volume Drug Device Combinations: Distribution by Type of Device
Table 19.104 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Table 19.105 Large Volume Drug Device Combinations: Distribution by Technology
Table 19.106 Large Volume Drug Device Combinations: Distribution by Route of Administration
Table 19.107 Large Volume Drug Device Combinations: Distribution by Method of Administration
Table 19.108 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Table 19.109 Large Volume Drug Device Combinations: Distribution by Type of Dose
Table 19.110 Large Volume Drug Device Combinations: Distribution by Storage Volume / Capacity (in mL)
Table 19.111 Large Volume Drug Device Combinations: Distribution by Usability
Table 19.112 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Table 19.113 Large Volume Drug Device Combinations: Distribution by Drug Container
Table 19.114 Most Active Players: Distribution by Number of Products Manufactured
Table 19.115 Autoinjectors: Distribution by Actuation Mechanism
Table 19.116 Autoinjectors: Distribution by Route of Administration
Table 19.117 Autoinjectors: Distribution by Type of Dose
Table 19.118 Autoinjectors: Distribution by Storage Volume / Capacity (in mL)
Table 19.119 Autoinjectors: Distribution by Usability
Table 19.120 Autoinjectors: Distribution by Type of Primary Container
Table 19.121 Autoinjectors: Distribution by Type of Feedback Mechanism
Table 19.122 Most Active players: Distribution by Number of Devices
Table 19.123 Pen Injectors: Distribution by Type of Dose
Table 19.124 Pen Injectors: Distribution by Storage Volume / Capacity (in ml)
Table 19.125 Pen Injectors: Distribution by Usability
Table 19.126 Most Active Players: Distribution by Number of Devices
Table 19.127 Needle Free Injection Systems: Distribution by Phase of Development
Table 19.128 Needle Free Injection Systems: Distribution by Actuation Mechanism
Table 19.129 Needle Free Injection Systems: Distribution by Therapeutic Area
Table 19.130 Needle Free Injection Systems: Distribution by Usability
Table 19.131 Most Active Players: Distribution by Number of Devices
Table 19.132 Novel Drug Reconstitution Systems: Distribution by Volume Storage / Capacity (in mL)
Table 19.133 Novel Drug Reconstitution Systems: Distribution by Usability
Table 19.134 Novel Drug Reconstitution Systems: Distribution by Type of Device
Table 19.135 Novel Drug Reconstitution Systems: Distribution by Type of Chamber
Table 19.136 Novel Drug Reconstitution Systems: Distribution by Type of Device and Chamber
Table 19.137 Novel Drug Reconstitution Systems: Distribution by Physical State of Drug
Table 19.138 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material
Table 19.139 Novel Drug Reconstitution Systems: Distribution by Container Fabrication Material and Usability
Table 19.140 Most Active Players: Distribution by Number of Devices
Table 19.141 Prefilled Syringes: Distribution by Storage Volume / Capacity (in ml)
Table 19.142 Prefilled Syringes: Distribution by Barrel Fabrication Material
Table 19.143 Prefilled Syringes: Distribution by Number of Barrel Chambers
Table 19.144 Prefilled Syringes: Distribution by Type of Needle System
Table 19.145 Most Active Players: Distribution by Number of Devices
Table 19.146 Implants: Distribution by Phase of Development
Table 19.147 Implants: Distribution by Therapeutic Area
Table 19.148 Implants: Distribution by Implant Material
Table 19.149 Implants: Distribution by Treatment Duration
Table 19.150 Implants: Distribution by Type of Delivery System
Table 19.151 Most Active Players: Distribution By number of Devices
Table 19.152 Global Approved Subcutaneous Biologics Market, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.153 Approved Subcutaneous Biologics Market: Distribution by Type of Biologic, 2022 and 2035
Table 19.154 Approved Subcutaneous Biologics Market for Antibodies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.155 Approved Subcutaneous Biologics Market for Nucleotides, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.156 Approved Subcutaneous Biologics Market for Proteins, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.157 Approved Subcutaneous Biologics Market for Vaccines, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.158 Approved Subcutaneous Biologics Market for Other Biologics, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.159 Approved Subcutaneous Biologics Market: Distribution by Type of Therapy, 2022 and 2035
Table 19.160 Approved Subcutaneous Biologics Market for Monotherapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.161 Approved Subcutaneous Biologics Market for Combination Therapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.162 Approved Subcutaneous Biologics Market for Monotherapies and Combination Therapies, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.163 Approved Subcutaneous Biologics Market: Distribution by Therapeutic Area, 2022 and 2035
Table 19.164 Approved Subcutaneous Biologics Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.165 Approved Subcutaneous Biologics Market for Blood Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.166 Approved Subcutaneous Biologics Market for Bone Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.167 Approved Subcutaneous Biologics Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.168 Approved Subcutaneous Biologics Market for Genetic Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.169 Approved Subcutaneous Biologics Market for Hormonal Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.170 Approved Subcutaneous Biologics Market for Infectious Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.171 Approved Subcutaneous Biologics Market for Inflammatory Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.172 Approved Subcutaneous Biologics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.173 Approved Subcutaneous Biologics Market for Neurological Disorders, Conservative, Base and Optimistic Scenario (USD Million), 2022-2035
Table 19.174 Approved Subcutaneous Biologics Market for Oncological Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.175 Approved Subcutaneous Biologics Market for Respiratory Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.176 Approved Subcutaneous Biologics Market for Women’s Health Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.177 Approved Subcutaneous Biologics Market for Other Disorders, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.178 Approved Subcutaneous Biologics Market: Distribution by Geographical Region, 2022 and 2035
Table 19.179 Approved Subcutaneous Biologics Market in North America, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.180 Approved Subcutaneous Biologics Market in Europe, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.181 Approved Subcutaneous Biologics Market in Asia, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.182 Approved Subcutaneous Biologics Market in Middle East and North Africa, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.183 Approved Subcutaneous Biologics Market in Latin America, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.184 Approved Subcutaneous Biologics Market in Rest of the World, Conservative, Base and Optimistic Scenario (USD Million),2022-2035
Table 19.185 AIMOVIG Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.186 AJOVY Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.187 Apidra (insulin glulisine), Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.188 Basaglar / Abrasia (EU) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.189 BENLYSTA (belimumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.190 BESREMi (ropeginterferon alfa-2b-njft) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.191 BIOTHRAX (Anthrax Vaccine Adsorbed) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.192 CABLIVI (Caplacizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.193 Cegfila Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.194 CIMZIA (certolizumab pegol) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.195 COSENTYX (secukinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.196 CRYSVITA (burosumab-twza) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.197 Cuvitru (immune globulin subcutaneous [human], 20% solution) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.198 DARZALEX FASPRO (daratumumab and hyaluronidase-fihj / DARZALEX SC Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.199 DENGVAXIA (Dengue Tetravalent Vaccine) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.200 DUPIXENT (dupilumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.201 EMGALITY (galcanezumab-gnlm) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.202 EMPAVELI (pegcetacoplan) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.203 Enbrel (etanercept) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.204 ENSPRYNG (satralizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.205 EVENITY (romosozumab-aqqg) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.206 FASENRA (benralizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.207 Fertavid (follitropin beta) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.208 FIASP (Insulin Aspart) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.209 Fulphila (pegfilgrastim-jmdb) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.210 Gamunex-C (Immune Globulin Injection [Human], 10% Caprylate /Chromatography Purified) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.211 GATTEX / Revestive (teduglutide [rDNA origin]) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.212 GIVLAARI (givosiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.213 HAEGARDA Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.214 HEMLIBRA (emicizumab-kxwh) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.215 Hepcludex (Bulevirtide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.216 Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.217 HYQVIA (Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.218 ILARIS (canakinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.219 ILUMYA (tildrakizumab-asmn) / Ilumetri Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.220 Kalbitor (ecallantide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.221 Kesimpta (ofatumumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.222 KEVZARA (sarilumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.223 KINERET (anakinra) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.224 Kyntheum / SILIQ / Lumicef (brodalumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.225 Leqvio (Inclisiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.226 Lonquex (lipegfilgrastim) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.227 Lyumjev (insulin lispro-aabc) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.228 Norditropin (somatropin) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.229 NPLATE (romiplostim) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.230 Nucala (mepolizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.231 OXLUMO (lumasiran) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.232 PALYNZIQ (pegvaliase-pqpz) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.233 Pergoveris (follitropin alfa / lutropin alfa) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.234 Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.235 PRALUENT (alirocumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.236 Prolia / Pralia (denosumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.237 REBLOZYL (luspatercept-aamt) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.238 REKOVELLE (follitropin delta) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.239 Repatha (evolocumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.240 RYZODEG 70/30 (insulin degludec and insulin aspart) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.241 Skyrizi (risankizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.242 SKYTROFA (lonapegsomatropin-tcgd) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.243 SOLIQUA 100/33 (insulin glargine & lixisenatide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.244 STELARA (ustekinumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.245 Strensiq (asfotase alfa) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.246 TAKHZYRO (lanadelumab-flyo) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.247 Taltz (ixekizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.248 TEGSEDI (inotersen) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.249 Toujeo (insulin glargine injection) U-300 Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.250 TREMFYA (guselkumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.251 TRESIBA (insulin degludec injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.252 Trulicity (dulaglutide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.253 TYMLOS (abaloparatide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.254 Tysabri (Natalizumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.255 Voxzogo (vosoritide) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.256 VYLEESI (bremelanotide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.257 XEMBIFY (immune globulin subcutaneous, human – klhw) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.258 Xgeva / RANMARK (denosumab) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.259 XULTOPHY® / IDegLira (insulin degludec and liraglutide injection) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.260 XYOSTED (testosterone enanthate) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.261 ZEGALOGUE (dasiglucagon) Sales Forecast, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.262 Global Subcutaneous Formulation Technologies Market, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.263 Subcutaneous Formulation Technologies Market: Distribution by Type of Payment, 2022-2035 (USD Million)
Table 19.264 Subcutaneous Formulation Technologies Market for Milestone Payments, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.265 Subcutaneous Formulation Technologies Market for Upfront Payments, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.266 Subcutaneous Formulation Technologies Market: Distribution by Fundamental Principle, 2022-2035 (USD Million)
Table 19.267 Subcutaneous Formulation Technologies Market for Amino Acid Interaction Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.268 Subcutaneous Formulation Technologies Market for Complex Formation Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.269 Subcutaneous Formulation Technologies Market for Encapsulation Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.270 Subcutaneous Formulation Technologies Market for Other Fundamental Principles, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.271 Subcutaneous Formulation Technologies Market: Distribution by End Users, 2022-2035 (USD Million)
Table 19.272 Subcutaneous Formulation Technologies Market for Biopharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.273 Subcutaneous Formulation Technologies Market for Biotechnology Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.274 Subcutaneous Formulation Technologies Market for Contract Development and Manufacturing Organizations, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.275 Subcutaneous Formulation Technologies Market for Educational Institutes, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.276 Subcutaneous Formulation Technologies Market for Investors, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.277 Subcutaneous Formulation Technologies Market for Pharmaceutical Companies, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.278 Subcutaneous Formulation Technologies Market for Research Institutes, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.279 Subcutaneous Formulation Technologies Market for Other End Users, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.280 Subcutaneous Formulation Technologies Market: Distribution by Therapeutic Area, 2022 and 2035
Table 19.281 Subcutaneous Formulation Technologies Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.282 Subcutaneous Formulation Technologies Market for Genetic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.283 Subcutaneous Formulation Technologies Market for Infectious Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.284 Subcutaneous Formulation Technologies Market for Metabolic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.285 Subcutaneous Formulation Technologies Market for Oncological Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.286 Subcutaneous Formulation Technologies Market for Ophthalmic Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.287 Subcutaneous Formulation Technologies Market for Other Disorders, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.288 Subcutaneous Formulation Technologies Market: Distribution by Geographical Regions, 2022 and 2035
Table 19.289 Subcutaneous Formulation Technologies Market for North America, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.290 Subcutaneous Formulation Technologies Market for Europe, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.291 Subcutaneous Formulation Technologies Market for Asia, Conservative, Base and Optimistic Scenario, 2022-2035 (USD Million)
Table 19.292 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.293 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.294 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.295 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.296 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.297 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.298 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.299 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.300 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.301 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.302 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.303 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.304 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.305 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.306 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.307 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.308 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.309 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.310 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.311 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.312 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.313 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.314 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.315 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.316 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.317 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.318 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.319 Global Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.320 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.321 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.322 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.323 Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.324 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.325 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.326 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.327 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.328 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.329 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.330 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.331 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia Pacific: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.332 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.333 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.334 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.335 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.336 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.337 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.338 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.339 Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.340 Global Large Volume Wearable Injectors Market for Insulin, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.341 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.342 Global Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.343 Large Volume Wearable Injectors Market for Insulin in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.344 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.345 Large Volume Wearable Injectors Market for Insulin in North America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.346 Large Volume Wearable Injectors Market for Insulin in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.347 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.348 Large Volume Wearable Injectors Market for Insulin in Europe: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.349 Large Volume Wearable Injectors Market for Insulin in Asia Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.350 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.351 Large Volume Wearable Injectors Market for Insulin in Asia Pacific: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.352 Large Volume Wearable Injectors Market for Insulin in Latin America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.353 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.354 Large Volume Wearable Injectors Market for Insulin in Latin America: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.355 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.356 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Type of Device, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.357 Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa: Distribution by Usability, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Million)
Table 19.358 Global Autoinjectors Market, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.359 Global Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.360 Global Disposable Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.361 Global Intramuscular Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.362 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.363 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.364 Autoinjectors Market for Anaphylaxis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.365 Autoinjectors Market for Anaphylaxis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.366 Autoinjectors Market for Anaphylaxis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.367 Autoinjectors Market for Anaphylaxis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.368 Global Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.369 Global Disposable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.370 Global Reusable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.371 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.372 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.373 Global Protein-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.374 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.375 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.376 Autoinjectors Market for Multiple Sclerosis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.377 Autoinjectors Market for Multiple Sclerosis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.378 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.379 Autoinjectors Market for Multiple Sclerosis in Rest of the World, 2021-2035 (USD Billion)
Table 19.380 Global Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.381 Global Disposable Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.382 Global Subcutaneous Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.383 Global Antibody-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.384 Global Small Molecule-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.385 Autoinjectors Market for Migraine in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.386 Autoinjectors Market for Migraine in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.387 Autoinjectors Market for Migraine in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.388 Autoinjectors Market for Migraine in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.389 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.390 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.391 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.392 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.393 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.394 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.395 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.396 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.397 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.398 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.399 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.400 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.401 Global Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.402 Global Disposable Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.403 Global Subcutaneous Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.404 Global Protein-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.405 Global Peptide-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.406 Autoinjectors Market for Diabetes in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.407 Autoinjectors Market for Diabetes in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.408 Autoinjectors Market for Diabetes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.409 Autoinjectors Market for Diabetes in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.410 Global Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.411 Global Disposable Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.412 Global Subcutaneous Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.413 Global Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.414 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.415 Global Protein-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.416 Global Antibody-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.417 Global Small Molecule-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.418 Autoinjectors Market for Other Indications in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.419 Autoinjectors Market for Other Indications in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.420 Autoinjectors Market for Other Indications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.421 Autoinjectors Market for Other Indications in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.422 Global Autoinjectors Market, 2021-2035 (Million Units)
Table 19.423 Global Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.424 Global Disposable Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.425 Global Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.426 Global Subcutaneous / Intramuscular Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.427 Global Small Molecule-based Autoinjectors Market for Anaphylaxis, 2021-2035 (Million Units)
Table 19.428 Autoinjectors Market for Anaphylaxis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.429 Autoinjectors Market for Anaphylaxis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.430 Autoinjectors Market for Anaphylaxis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.431 Autoinjectors Market for Anaphylaxis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.432 Global Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.433 Global Disposable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.434 Global Reusable Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.435 Global Intramuscular Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.436 Global Subcutaneous Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.437 Global Protein-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.438 Global Peptide-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.439 Global Antibody-based Autoinjectors Market for Multiple Sclerosis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.440 Autoinjectors Market for Multiple Sclerosis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.441 Autoinjectors Market for Multiple Sclerosis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.442 Autoinjectors Market for Multiple Sclerosis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.443 Autoinjectors Market for Multiple Sclerosis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.444 Global Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.445 Global Disposable Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.446 Global Subcutaneous Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.447 Global Antibody-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.448 Global Small Molecule-based Autoinjectors Market for Migraine, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.449 Autoinjectors Market for Migraine in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.450 Autoinjectors Market for Migraine in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.451 Autoinjectors Market for Migraine in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.452 Autoinjectors Market for Migraine in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.453 Global Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.454 Global Disposable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.455 Global Reusable Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.456 Global Subcutaneous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.457 Global Subcutaneous / Intravenous Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.458 Global Antibody-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.459 Global Protein-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.460 Global Small Molecule-based Autoinjectors Market for Rheumatoid and Psoriatic Arthritis, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.461 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.462 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.463 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.464 Autoinjectors Market for Rheumatoid and Psoriatic Arthritis in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.465 Global Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.466 Global Disposable Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.467 Global Subcutaneous Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.468 Global Protein-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.469 Global Peptide-based Autoinjectors Market for Diabetes, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.470 Autoinjectors Market for Diabetes in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.471 Autoinjectors Market for Diabetes in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.472 Autoinjectors Market for Diabetes in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.473 Autoinjectors Market for Diabetes in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.474 Global Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.475 Global Disposable Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (USD Billion)
Table 19.476 Global Subcutaneous Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.477 Global Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.478 Global Subcutaneous / Intramuscular Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.479 Global Protein-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.480 Global Antibody-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.481 Global Small Molecule-based Autoinjectors Market for Other Indications, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.482 Autoinjectors Market for Other Indications in North America, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.483 Autoinjectors Market for Other Indications in Europe, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.484 Autoinjectors Market for Other Indications in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.485 Autoinjectors Market for Other Indications in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2035 (Million Units)
Table 19.486 Prefilled Syringes Price, 2020-2030: Conservative, Base and Optimistic Scenarios (USD per unit)
Table 19.487 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.488 Global Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2020-2030 (Million, Units)
Table 19.489 Prefilled Syringes Market: Distribution by Type of Syringe Barrel Material, 2020, 2025 and 2030 (USD Million)
Table 19.490 Prefilled Syringes Market: Distribution by Type of Chamber System, 2020, 2025 and 2030 (USD Million)
Table 19.491 Prefilled Syringes Market: Distribution by Type of Pharmacological Molecule, 2020, 2025 and 2030 (USD Million)
Table 19.492 Prefilled Syringes Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030
Table 19.493 Global Needle-free Injection Systems Market, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.494 Global Needle-free Injection Systems Market: Distribution by Actuation Mechanism, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.495 Global Needle-free Injection Systems Market: Distribution by Target Therapeutic Area, Conservative, Base and Optimistic Scenario, 2020-2030 (USD Million)
Table 19.496 Global Novel Drug Reconstitution Systems Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.497 Global Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.498 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Physical State of Drug
Table 19.499 Dual Chamber Prefilled Syringes Market for Liquid / Powder Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.500 Dual Chamber Prefilled Syringes Market for Liquid / Liquid Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.501 Dual Chamber Prefilled Syringes Market, 2021 and2030: Distribution by Type of Fabrication Material Used
Table 19.502 Glass Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.503 Plastic Dual Chamber Prefilled Syringes Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.504 Dual Chamber Prefilled Syringes Market, 2021-2030: Distribution by Volume
Table 19.505 Dual Chamber Prefilled Syringes Market for <1 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.506 Dual Chamber Prefilled Syringes Market for 1-2.5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.507 Dual Chamber Prefilled Syringes Market for 2.5-5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.508 Dual Chamber Prefilled Syringes Market for >5 mL Syringes, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.509 Dual Chamber Prefilled Syringes Market, 2021 and 2030: Distribution by Geography
Table 19.510 Dual Chamber Prefilled Syringes Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.511 Dual Chamber Prefilled Syringes Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.512 Dual Chamber Prefilled Syringes Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.513 Dual Chamber Prefilled Syringes Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.514 Dual Chamber Prefilled Syringes Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.515 Global Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.516 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Physical State of Drug
Table 19.517 Dual Chamber Cartridges Market for Liquid / Powder Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.518 Dual Chamber Cartridges Market for Liquid / Liquid Drugs, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.519 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Type of Fabrication Material Used
Table 19.520 Glass Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.521 Plastic Dual Chamber Cartridges Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.522 Dual Chamber Cartridges Market, 2021 and 2030: Distribution by Volume
Table 19.523 Dual Chamber Cartridges Market for <1 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.524 Dual Chamber Cartridges Market for 1-2.5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.525 Dual Chamber Cartridges Market for 2.5-5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.526 Dual Chamber Cartridges Market for >5 mL Cartridges, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.527 Dual Chamber Cartridges Market, 2021-2030: Distribution by Geography
Table 19.528 Dual Chamber Cartridges Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.529 Dual Chamber Cartridges Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.530 Dual Chamber Cartridges Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.531 Dual Chamber Cartridges Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.532 Dual Chamber Cartridges Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.533 Global Dual / Multi Chamber Infusion Bags Market, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.534 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Physical State of Drug
Table 19.535 Dual / Multi Chamber Infusion Bags Market for Liquid Mixture, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.536 Dual / Multi Chamber Infusion Bags Market for Frozen Mixture, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.537 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Type of Plastic
Table 19.538 Dual / Multi Chamber Infusion Bags Market for Ethylene Vinyl Acetate Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.539 Dual / Multi Chamber Infusion Bags Market for Polypropylene Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.540 Dual / Multi Chamber Infusion Bags Market for Polyvinyl Chloride Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.541 Dual / Multi Chamber Infusion Bags Market for Other Plastic Materials Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.542 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Volume
Table 19.543 Dual / Multi Chamber Infusion Bags Market for <250 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.544 Dual / Multi Chamber Infusion Bags Market for 250-500 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.545 Dual / Multi Chamber Infusion Bags Market for 501-1,000 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.546 Dual / Multi Chamber Infusion Bags Market for >1,000 mL Infusion Bags, Conservative, Base and Optimistic Scenario, 2021- 2030 (USD Billion)
Table 19.547 Dual / Multi Chamber Infusion Bags Market, 2021-2030: Distribution by Geography
Table 19.548 Dual / Multi Chamber Infusion Bags Market in North America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.549 Dual / Multi Chamber Infusion Bags Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.550 Dual / Multi Chamber Infusion Bags Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.551 Dual / Multi Chamber Infusion Bags Market in Latin America, Conservative, Base and Optimistic Scenario, 2021-2030 (USD Billion)
Table 19.552 Dual / Multi Chamber Infusion Bags Market in Middle East and Africa, Conservative, Base and Optimistic Scenario, 2021-2030

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3D Medicines
2. 89bio
3. AB2 Bio
4. Abbott Laboratories
5. AbbVie
6. Ablynx
7. AC Immune
8. Acceleron Pharma
9. Accord Healthcare
10. Acer Therapeutics
11. ACG Management
12. Activa Brand Products
13. Adisave
14. Adocia
15. Affibody
16. Affinivax
17. Aguettant
18. Aijex Pharma International
19. Ajinomoto Bio-Pharma Services
20. Akcea Therapeutics
21. Akero Therapeutics
22. Akeso
23. Akeso Tiancheng
24. AKRA DERMOJET
25. AktiVax
26. Alder BioPharmaceuticals
27. Alexion
28. Alexion Pharmaceuticals
29. Alkermes
30. Allakos
31. Allergan
32. Alnylam Pharmaceuticals
33. Alopexx Oncology
34. Alphamab
35. Alteogen
36. Altor BioScience
37. ALTuCELL 
38. Altus Pharmaceuticals
39. Alvogen
40. ALZA 
41. AMAG Pharmaceuticals
42. Amedra Pharmaceuticals 
43. Amgen
44. Amgen Astellas BioPharma
45. AnaptysBio
46. Andes Biotechnologies
47. Androsystems
48. Antares Pharma
49. Anterogen
50. Anthera Pharmaceuticals
51. AOP Orphan Pharmaceuticals
52. Apellis Pharmaceuticals
53. Aphios
54. Apobiologix 
55. Apotex
56. Araclon Biotech
57. Arecor
58. argenx
59. ARMO BioSciences
60. Arrowhead Pharmaceuticals
61. Arsia Therapeutics
62. ARTE 
63. Arthritis Innovation Corporation (AIC)
64. Asahi Kasei
65. Ascendis Pharma
66. ASIT Biotech
67. ASLAN Pharmaceuticals
68. Aspen Pharmacare
69. Astellas Pharma
70. AstraZeneca
71. Athyrium Capital Management
72. Atridia
73. Avadel Pharmaceuticals
74. Avant Medical Corporation
75. Avid Bioservices
76. Avillion
77. Axxia Pharmaceuticals
78. BASF 
79. Bavarian Nordic
80. Baxalta
81. Bay City Capital
82. Bayer
83. Becton Dickinson
84. Beijing Dongfang Biotech
85. Beijing Northland Biotech
86. Bespak
87. Beta-Cell
88. Beta-O2 Technologies 
89. Bill & Melinda Gates Foundation
90. Bill & Melinda Gates Foundation
91. Bioam Gestion
92. BioAtla
93. BIOCAD
94. Biocorp
95. Biogen
96. Bioject Medical Technologies
97. BioMarin Pharmaceutical
98. Biomay
99. BioMimetix
100. BioValve
101. Bird Rock Bio
102. BJ Bioscience
103. Boehringer Ingelheim
104. Boston Pharmaceuticals
105. Braeburn Pharmaceuticals
106. Bristol-Myers Squibb
107. Britannia Pharmaceuticals
108. Broadfin Capital
109. Cadila Pharmaceuticals
110. Calibr
111. Cam Med
112. Cambridge Antibody Technology
113. Cambridge Consultants
114. Camurus
115. CAPRISA
116. Carbion
117. Catalyst Biosciences
118. CDC Enterprises
119. Celgene
120. Celldex Therapeutics
121. Cellnovo
122. Centocor Ortho Biotech
123. Central Texas Angel Network 
124. CeQur
125. Changchun BCHT Biotechnology
126. Chondrial Therapeutics
127. Chugai Pharmaceutical
128. CinnaGen
129. CiVi Biopharma
130. Cleveland BioLabs
131. Clinigen
132. CM Biomaterials
133. CM-CIC Innovation
134. College Diabetes Network
135. Companion Medical
136. Complex Biosystems
137. Copernicus
138. Corbion
139. Corvidia Therapeutics
140. Creative Biolabs
141. Creative BioMart
142. Crescendo Pharmaceuticals
143. Crossject
144. CSL Behring
145. CSPC Pharmaceutical 
146. C-Tri
147. Cumberland Pharmaceuticals
148. CuraVac
149. CytoDyn
150. Cytori Therapeutics
151. Daiichi Sankyo
152. Daikyo Seiko
153. DALI Medical Devices
154. D'Antonio Consultants International
155. Debiotech
156. Deerfield Management
157. Delpor
158. DelSiTech
159. Dermira
160. Desentum
161. DiaMedica Therapeutics
162. Diamesco
163. Diasome Pharmaceuticals
164. Dicerna Pharmaceuticals
165. Digital Medics
166. Digna Biotech
167. Dongbao
168. Dr. Reddy's Laboratories
169. DSM Venturing
170. Duoject Medical Systems
171. DURECT
172. Dyax (acquired by Shire)
173. Eagle Pharmaceuticals
174. Eagle Pharmaceuticals
175. Eddingpharm
176. Eiger BioPharmaceuticals
177. Eisai
178. Elcam Medical
179. Elektrofi
180. Eli Lilly
181. EMD Serono
182. Emergent BioSolutions
183. Emperra
184. Enable Injections
185. Endo Pharmaceuticals
186. Enesi Pharma
187. EOC Pharma
188. Epilepsy Foundation
189. Etubics 
190. European Pharma Group
191. Ever Supreme Bio Technology
192. Evive Biotech
193. Excelse Bio
194. EyeTech
195. Felton International
196. Ferring Pharmaceuticals
197. Finox Biotech
198. Flamel Technologies
199. Flowonix Medical
200. FluGen
201. Fresenius Kabi
202. FUJIFILM Diosynth Biotechnologies
203. Future Injection Technologies
204. Fuze
205. GALVmed
206. GC Pharma
207. GeneCure Biotechnologies
208. Genentech
209. Generon
210. Genexine
211. Genmab
212. Genocea Biosciences
213. Genor Biopharma
214. GEROPHARM
215. Gerresheimer
216. Gilde Healthcare 
217. Gilead Sciences
218. GlaxoSmithKline
219. Globe Medical Tech
220. GlobeImmune
221. Grifols
222. Guangdong Xiangxue Precision Medical Technology
223. HAL Allergy
224. Halozyme Therapeutics
225. Hanall Biopharma
226. Hanmi Pharmaceutical
227. Harbour BioMed
228. Haselmeier
229. Health Decisions
230. Hengrui Therapeutics
231. HengRui USA
232. Hercules Capital
233. Heron Therapeutics
234. Hikma Pharmaceuticals
235. Horizon Therapeutics
236. Hospira
237. Human Genome Sciences
238. IDINVEST Partners
239. ILTOO Pharma
240. Il-Yang Pharmaceutical
241. Immunex
242. ImmunoForge
243. Immunomedics
244. ImmunoVaccine Technologies
245. ImmuPharma
246. ImmusanT
247. Immutep
248. Impax Laboratories
249. Incepta Pharmaceuticals
250. Indivior
251. Inhibrx
252. Injecto
253. INJEX Pharma
254. INmune Bio
255. Inmunotek
256. InnoCore Pharmaceuticals
257. Innovare R&D
258. Innovate UK
259. Innovent Biologics
260. Inolife Sciences
261. Inovio Pharmaceuticals
262. i-novion
263. Insense
264. Insulet 
265. Insuline Medical
266. Intarcia Therapeutics
267. Intas Pharmaceuticals
268. Integrity Bio
269. Intrexon
270. IO Biotech
271. Ionis Pharmaceuticals
272. Ipsen
273. ISA Pharmaceuticals 
274. ISU Abxis
275. Izana Bioscience
276. Janssen
277. Janssen Biotech
278. Janus Capital
279. JCR Pharmaceuticals
280. JDRF
281. Jiangsu Delfu Medical Device
282. Jiangsu Hengrui Medicine
283. Jiangsu Wan Hai Medical Instruments
284. JO Pharma 
285. Johnson & Johnson
286. Juvenile Diabetes Research Foundation
287. Kaléo 
288. Kangstem Biotech
289. Kastle Therapeutics
290. KBI Biopharma
291. Kedrion Biopharma
292. Kinevant Sciences
293. King Pharmaceuticals
294. Kingsbury Capital Partners
295. Kiniksa Pharmaceuticals
296. Kitasato Daiichi Sankyo Vaccine
297. Knight Therapeutics
298. Kolltan Pharmaceuticals
299. Kymab
300. Kyowa Hakko Kirin
301. Kyowa Kirin 
302. Laboratorios Liomont
303. Lapeyronie Hospital
304. Larimar Therapeutics
305. Lenis Medical
306. LEO Pharma
307. Leukocare Biotechnology
308. LIB Therapeutics
309. Lindy Biosciences
310. Lineage Therapeutics
311. Lundbeck
312. Lupin
313. Luye Pharma
314. Lynkogen
315. Malvern Panalytical
316. Manchester Institute of Biotechnology
317. Maruho
318. Maruishi Pharmaceutical
319. Massachusetts Institute of Technology
320. MaxiVAX
321. McGill University
322. McNair Group
323. Medac Pharma
324. Medical International Technology
325. Medicalchain
326. Medicines Patent Pool (MPP)
327. Medicom Innovation Partner
328. MedImmune
329. MedinCell
330. Medipacs
331. Medison Pharma
332. MedPro 
333. Medtronic
334. Medtrum
335. Megapharm
336. Merck
337. Merck KGaA 
338. Merck Serono
339. Merieux Développement
340. MGlas 
341. MicroVAX
342. Mika Medical
343. MilliporeSigma
344. Miracle Medical
345. Mitsubishi Gas Chemical
346. Mitsubishi Tanabe Pharma
347. MJ Biopharm
348. Momenta Pharmaceuticals
349. Morphogenesis
350. MorphoSys
351. Mundipharma
352. Mylan
353. Nano Precision Medical
354. NantCell
355. National Cancer Institute
356. National Institute of Allergy and Infectious Diseases
357. National Institute of Diabetes and Digestive and Kidney Diseases 
358. National Institute of Neurological Disorders and Stroke
359. National Institutes of Health
360. Nektar Therapeutics
361. Nemera
362. Neoleukin Therapeutics
363. Neumedicines
364. Neurimmune
365. NeuroDerm
366. NGM Biopharmaceuticals
367. Ningbo Zhengli Pharmaceutical Packing
368. Nippon Organon
369. Nipro Medical 
370. Nordic Group
371. Novartis
372. Novimmune
373. Novo Nordisk
374. NPS Pharmaceuticals
375. Nuance Designs 
376. Numab
377. Nuova Ompi
378. OBI Pharma
379. OliPass
380. OliX Pharmaceuticals
381. Omeros 
382. Ompi
383. Oncolix
384. Ono Pharmaceutical
385. OPKO Health
386. OrbiMed
387. Orphan Technologies
388. Orphan Technologies
389. Otsuka Pharmaceutical
390. Oval Medical Technologies
391. Owen Mumford
392. Oxford Finance 
393. PA Consulting 
394. Pacira BioSciences
395. Palmetto Partners
396. Par Pharmaceutical
397. PaxVax
398. Pendiq
399. Penjet
400. Pfizer
401. PharmaJet
402. Pharmakon Advisors
403. PharmaSens
404. Pharmstandard
405. PhaseBio Pharmaceuticals
406. PHC Injection Device Technologies
407. Philogen
408. Phoundry Pharmaceuticals
409. Plas-Tech Engineering
410. Polfa Tarchomin
411. Population Council
412. Portal Instruments
413. Precision NanoSystems
414. Primequal
415. ProJect Pharmaceutics
416. Prolynx
417. Promius Pharma
418. Protagonist Therapeutics
419. ProteoThera
420. Provenance Biopharmaceuticals
421. Pulse NeedleFree Systems
422. QS Medical Technology
423. Qu Biologics
424. RA Capital Management
425. Ra Pharmaceuticals
426. Radius Health
427. Receptos
428. Recon Therapeutics
429. Redmile Group
430. ReForm Biologics
431. Regeneron Pharmaceuticals
432. REMD Biotherapeutics
433. RemeGen
434. Rentschler Biotechnologie
435. Revance Therapeutics
436. Revolutions Medical
437. Rhône-Poulenc Rorer
438. Rhythm Pharmaceuticals
439. RMS Medical Products
440. Roche
441. Rock Springs Capital
442. Roselabs Bioscience
443. ROXALL Medizin
444. R-Pharm
445. Sabby Management
446. Safe Save Medical Cell Sciences & Technology
447. Salix Pharmaceuticals
448. Samsung Bioepis
449. Sandoz
450. Sanofi
451. Sanofi Pasteur
452. Santen Pharmaceutical 
453. Schering-Plough 
454. Schott
455. Scripps Research Institute
456. Sensile Medical
457. Seqirus
458. Serina Therapeutics
459. Sernova
460. Serum Institute of India
461. Sewa Medicals
462. Shandong Pharmaceutical Glass
463. Shandong Weigao
464. Shandong Zibo Minkang Pharmaceutical Packing
465. Shanghai Dahua Pharmaceutical
466. Shanghai JMT-Bio
467. Shanghai Junshi Biosciences
468. Shanghai Umitai Medical Technology 
469. Shenzhen Geno-immune Medical Institute
470. Shenzhen Salubris Pharmaceuticals
471. Shin Yan Sheno Precision Industrial
472. Shionogi
473. Shire
474. SHL Medical
475. Shreya Life Sciences
476. Silicon Valley Bank
477. Sinocelltech
478. SiO2 Medical Products
479. SK Chemicals
480. Société Générale Asset Management
481. Sofinnova Partners
482. Solteam Medical
483. SOOIL Development
484. Sosei Heptares
485. SOTIO
486. Spectrum Pharmaceuticals
487. Square Pharmaceuticals
488. STADA Arzneimittel
489. Statera Biopharma
490. SteadyMed Therapeutics
491. Stemirna Therapeutics
492. Strongbridge Biopharma
493. Subcuject
494. Sumitomo Dainippon Pharma
495. Sun Pharmaceutical Industries
496. Sun Yat-sen University
497. Swedish Orphan Biovitrum
498. Synermore Biologics
499. Synthon Hispania
500. Taisei Kako
501. Taisho Pharmaceutical
502. Takeda Pharmaceutical
503. Talecris Biotherapeutics
504. Tandem Diabetes Care
505. Tasly Transgene Tianjin BioPharmaceutical
506. Technical University of Munich
507. Telegraph Hill Partners
508. TerSera Therapeutics
509. Terumo
510. Tetris Pharma
511. Teva Pharmaceuticals
512. Texan Allergy & Sinus Center
513. Texas Diabetes Institute
514. Texas Emerging Technologies Fund
515. The National Institute for Health and Care Excellence
516. The National Medical Products
517. The National Medical Products Administration
518. The Wyss Institute at Harvard University
519. TheraCyte
520. Theralpha
521. Tianjin SinoBiotech
522. Titan Pharmaceuticals
523. Tonghua Dongbao
524. Torii Pharmaceutical
525. Touche Medical
526. TRACON Pharmaceuticals
527. Transcoject
528. Transgene
529. Travere Therapeutics
530. TREOS Bio
531. TRIO Pharmaceuticals
532. Tyfill Pharmapack
533. TYME Technologies
534. U.S. Medical Instruments
535. UCB Pharma
536. Ultragenyx Pharmaceutical
537. Uman Pharma
538. Uni-Bio Science Group
539. Unilever
540. Unilife 
541. Union Medico
542. United BioPharma
543. United Therapeutics
544. University of Colorado
545. University of Texas Health Science Center
546. US WorldMeds
547. Vaccine Research Center (VRC)
548. Valeant Pharmaceuticals 
549. Valeritas
550. VectivBio
551. Venrock
552. Ventana Medical Systems
553. Vetter Pharma
554. ViaCyte
555. ViCentra
556. Viela Bio
557. ViiV Healthcare
558. ViroMed
559. ViroPharma
560. Visus Therapeutics
561. Vitaeris
562. Vivo Capital
563. Wanhai Medical
564. West Pharmaceutical Services
565. Wild Basin Investments
566. XBiotech
567. Xellia Pharmaceuticals
568. XEME Biopharma
569. Xencor
570. Xeris Pharmaceuticals
571. YangZhong Wealth Metal
572. Youlyy Industrial
573. Ypsomed
574. Zensun
575. Zogenix
576. Zweite TechnoStart Ventures Fonds